

Ensuring no one faces kidney disease alone

Impact report and annual accounts 2025



Kidney Care UK Trustees' report and financial statements for the year ended 31 December 2025

The British Kidney Patient Association operating as Kidney Care UK
(a company limited by guarantee) Registered number: 1228114
Charity number: 270288 Charity number (Scotland): SC048198

Contents

4

Foreword from our CEO and Chair of Trustees

10

Trustees statement

12

2025 at a glance

14

How we supported patients and their families in 2025

15

How we spent our funds in 2025

16

Our Patient Support Services helped to change lives

28

Providing access to trusted information when and how patients want it

32

Working in partnership to improve health and care services across the UK

36

Representing the patient voice and campaigning for change

40

A #BloodyAmazing year for our awareness and prevention campaign

42

Managing our charity effectively and efficiently

44

Thank you to our generous fundraisers, donors and supporters

50

Looking ahead to 2026: our aims and goals

52

Our finances: financial review of the year

59

Reference and administrative details of the charity, its trustees and advisors

61

Auditors' report

66

Statement of financial activities

67

Balance sheet

69

Statement of cashflows

70

Notes to the financial statements





Foreword from our CEO, Paul Bristow

No one should underestimate the challenges facing kidney health services in the UK and the impact of living with kidney disease at this challenging time for the NHS and social care. We continue to see too many people at risk of kidney disease or facing kidney failure being diagnosed late, and prevention and early intervention programmes are not universally delivered as we would wish to see. Every day we hear from people and families who are struggling to cope with life with kidney disease in an environment where finances are challenging and better care coordination and access to psychological and social support would make such a difference.

As always, Kidney Care UK has continued to be there to help; 2025 saw us provide advice, guidance and support to more patients and families than ever before. We also reached a significant milestone for any organisation, but especially one that relies entirely on the generosity of its supporters to sustain and advance its work: our 50th year as the UK's leading kidney patient support charity. Although we have grown significantly, in essence we remain the same charity founded by a mother, Elizabeth Ward, who was determined to fight for her son's care and quality of life. In celebration of this, for the first time in our history, we surpassed £5m in income. We also maintained our expenditure on charitable activities at £5.66m in 2024 to £5.6m in 2025 and provided personal one-to-one support to more than 11,500 individuals and families. We are incredibly grateful to every single one of our fantastic supporters who help us be there for everyone that needs our support. These critical funds enable us to sustain and advance the support we provide at a time when it is needed more than ever.

In 2025, highlights included:

- £5.6m spent supporting more than 11,500 patients and families
- Nearly £1.2m in welfare and benefits income secured for patients who would otherwise miss out on financial support they were entitled to
- More than 1 million patient information resources accessed and more than 2.2 million unique visitors to our website
- Nearly 275,000 people completed our digital Kidney Health Checker thanks to our #BloodyAmazingKidneys campaign
- Over 20,000 donations from our generous supporters and significant funding from our partners helping us to generate £4.4m.

We were delighted to see the impact of the significant expansion of our welfare and wellbeing service, which originally launched in Wales in 2023 and provides in-depth, personal support for everyone preparing for or receiving treatment for kidney failure. As a result, 2025 saw us doubling the size of our Patient Support & Advocacy teams working in communities across the UK and increasing our presence in healthcare settings across Scotland, England and Wales, which allowed us to reach and directly support nearly 14,000 patients and families.

and Chair of Trustees, Dr Graham Lipkin



We also saw significant demand for our freephone patient Support Line with over 12,359 people supported in 2025. This is the equivalent to someone contacting us every nine minutes because they need the support of someone who “gets” kidney disease and understands the challenges of living with the condition. Our growth wasn’t just about greater personal one-to-one support. We also developed our information and communication channels to ensure people are able to access the information they want, in a format that suits them, when they want it. We continued to improve our website and digital support, resulting in an increase in unique website visitors of over 47%, to just shy of 2.2 million. In particular, our Kidney Kitchen resource reached more patients and healthcare professionals than ever before, with a 20% increase to 456,000 unique visitors in 2025.

Our partnership with the UK Kidney Association also expanded as we sought to ensure high quality, trusted information is available to all patients wherever they receive their care, with over 389,000 leaflets distributed to individuals and hospitals across the UK. This partnership approach of working with healthcare professionals and organisations to improve kidney services saw the ongoing development of our national service improvement project – Transform AKC – to improve the quality of advanced kidney care clinics, when anxious patients and families are having to make decisions about treatment and lifestyle choices.




We continued the expansion of our hugely successful national awareness campaign – #BloodyAmazingKidneys. The campaign continues to raise awareness, providing individuals access to a quick and simple online Kidney Health Checker to see if they are at increased risk of CKD and helping them to discuss this with their GP. By the end of the year almost 275,000 people had completed a kidney health check with around half of them being at higher risk, and we were delighted to hear that the campaign had won a Global Boehringer Ingelheim award for innovation and awareness.

To support these developments, we have continued to make sure our organisation infrastructure is robust enough to sustain the growth in our services, so our operation remains efficient. This ensures our donors remain confident that every pound we receive is well spent, and that our values and staff wellbeing are prioritised.

As we reach our half-century, Kidney Care UK starts the new year a bigger, better charity, having supported more patients and families than ever before. While we have achieved a great deal, we know that there is so much more to be done to help kidney patients and their families live well with kidney disease. The future remains uncertain and challenging, but with the continued support and generosity of our supporters and staff, who make it all possible, we aim to celebrate our next 50 years by helping more patients than ever before and ensuring no one has to face kidney disease alone.



Paul Bristow, Chief Executive


Dr. G.W. Lipkin

Dr Graham Lipkin MB ChB, BSc, MD, FRCP (UK), Chair of Trustees





As we reach our half-century, Kidney Care UK starts the new year a bigger, better charity, having supported more patients and families than ever before. While we have achieved a great deal, we know that there is so much more to be done to help kidney patients and their families live well with kidney disease



Our vision: all kidney patients can live their life to the full

Our mission: to improve the quality of life for everyone affected by kidney disease

Kidney Care UK is the UK's leading kidney patient support charity, working to improve the quality of life for everyone affected by kidney disease and raising awareness of kidney disease amongst the wider public. We provide practical, financial and emotional support to patients and their families and work in partnership with health professionals and statutory bodies to improve the access to and quality of health and care services. We also represent the patient voice in campaigning for change in policy and practice.

A diagnosis of CKD can be devastating, placing a considerable toll on patients and their loved ones. The condition affects every aspect of an individual's life including physical health, emotional wellbeing, finances and relationships, as well as employment and lifestyle. We work every day to change lives for patients, whatever their age, wherever they are in the UK and at whatever stage of the disease they might be. We believe no one should face kidney disease alone.



Trustees statement

The Trustees (who are also directors of the Charity for the purposes of Company Law) present their annual report, which incorporates the Directors' Report, the Strategic Report, and the financial statements of The British Kidney Patient Association (BKPA), operating as Kidney Care UK, for the year ended 31 December 2025.

The annual report and financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice (SORP 2019) applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Since the charitable company qualifies as medium under section 382, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 is included. The Strategic Report comprises Our impact in 2025, Our Financial Review and Our Principal Risks and Controls. The legal status and governance structure is explained in the "Structure, governance and management" section of this report on pages 68 to 70.

The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission in determining the activities undertaken by the charity.

Our charitable objects as set out in our articles of association are:

1

To educate and inform the public regarding all forms of kidney and associated disorders.

2

To promote the welfare of persons suffering from kidney and renal diseases or associated disorders ("Kidney Patients") including providing them with financial assistance.

3

To make grants to hospitals for new buildings and other construction works for kidney units, for facilities for kidney transplantation, dialysis and their renal treatment and to meet cost of employing personnel to provide renal services.

4

To fund research for the benefit of kidney patients.

Kidney Care UK 5 year strategy (2021-2025)

Strategic objectives:

To reach and engage more individuals and families living with chronic kidney disease (CKD).

To work in partnership to improve the way kidney patients are cared for across the UK.

To ensure patient views are effectively represented and campaign for better patient care.

To manage our Charity as effectively and efficiently as possible.

To inspire more people to support our work and develop a mature fundraising portfolio.



2025 at a glance



£5.6million
spent on charitable activities



**More than
11,500**

kidney patients and
their families
helped

£3.6million

invested in staff and
care services for
patients



**More than
1 million**
patient information
resources accessed



1,447

individuals given help
and financial
support

£458k

given in grants to
help people cope
with unexpected bills



More than £2.4million
in benefits income secured for families facing hardship

4,589

fundraisers making
it all possible



Over

5,700

people supported
with Counselling and
Patient Support &
Advocacy



12,873

Support Line users

14,675

people in our online community
(an increase of 13%)



995

pieces of media coverage
seen by 77 million people

274,369

Health Checker
completions



Our social media audience grew by

23%



Our total income in 2025 was


£5,040,719

(an increase of 29%)



How we supported patients and their families in 2025

Kidney disease affects more than 7 million people in the UK, equivalent to 1 in every 10 people, with around half of those living with the more advanced stages of chronic kidney disease (CKD). Kidney disease impacts all aspects of life, with individuals living with the disease more likely to be economically disadvantaged, and more likely to experience low mood and depression.



How we spent our funds in 2025



Counselling

£172,238 allocated for counselling services.



Patient Support & Advocacy

£1,862,784 dedicated to Patient Support & Advocacy.



Campaigning and Policy

£226,406 invested in campaigning and policy initiatives.



Patient Information Resources

£749,119 spent on providing patient information resources.



Patient Support (Support Line)

£364,031 allocated for patient support, including the Support Line.



Patient Care Projects

£76,454 dedicated to patient care projects and renal staff posts.



Partnerships

£122,105 invested in building partnerships.



Patient Support Costs

£1,333,713 allocated for patient support costs.



Individual Patient Grants

£693,885 spent on individual patient grants.



Our Patient Support Services helped to change lives

As the UK's leading kidney patient support charity, our range of direct patient support services provide a vital lifeline for thousands of people with kidney disease and their loved ones. A diagnosis of kidney disease doesn't just affect the person with the condition; the impact of their diagnosis can be felt by partners, parents, children and wider family members. Concerns about paying bills, the physical and emotional toll kidney disease has, making choices about treatments, lifestyle and dietary changes – these are all areas we at Kidney Care UK can help with.



“With only around 1 in 4 people with kidney failure able to work, just remaining afloat can be virtually impossible for many of the people we are here to support.

Securing financial stability, navigating complex benefit forms and welfare systems that often work against our community, and just being able to maintain a feeling of hope when times are hard can often feel out of reach. We're here to ensure that no one with kidney disease has to face these challenges alone.”

Sarah Oakley, Director of Patient Support Services

Our Support Line: provided information and advice to 12,000 people

After launching in the summer of 2024 thanks to philanthropic funding, our Support Line is now firmly established as the easy to “go to source” of information, advice and support for anyone affected by CKD. Our team of trained advisers – most of whom have personal experience of the impact of kidney disease – ensure patients and their families receive friendly, compassionate responses backed with accurate and trusted information and access to the Charity's wider support services.

In total in 2025, the Support Line team helped 12,359 people by telephone and email, the equivalent of one person every nine minutes. An important role for the Support Line is providing information and reassurance for people newly diagnosed with CKD and approximately 10% of the people contacting us are those who had recently discovered they had CKD, many by reading information in their medical notes or via the NHS App, with no explanation from their doctor.

We are here for kidney patients no matter what stage of CKD they have

Around one third of contacts were from patients who had received a CKD diagnosis from their doctor or other healthcare professional and required further support and guidance as to what this diagnosis meant for them. Many people have concerns around disease progression, with lots of questions about advice on diet and lifestyle changes to maintain kidney health. Understandably, many patients and loved ones are left feeling anxious and concerned about the future and this is when they contact the Support Line.



In 2025 there were
12,359 people
supported via telephone or
email through our Support Line.
That's equivalent to one
person every nine minutes.



One Saturday evening, Richard received a text message from his surgery informing him that he had CKD stage 3. This unexpected message came as a total shock and he was unable to book a GP appointment for some time, so he contacted the Support Line for guidance, reassurance and advice on his next steps. Following a long chat, we emailed Richard with all the information we'd discussed so he could refer to this when speaking to his GP.

“ Thank you so much for your advice today and the email. I have been very worried about my illness until today. I can now adjust my lifestyle and hopefully slow this illness.

Richard ”

Our Patient Support & Advocacy Service helped thousands face the everyday challenges of kidney disease

Across the four nations we are proud to have supported more than 13,000 people affected by CKD in 2025, providing information, advice and support through our community-based Patient Support & Advocacy Service.

Our knowledgeable, compassionate Patient Support & Advocacy Officers are frequently seen in renal units, addressing need directly where it is most acute, making sure dialysis patients know they have someone on their side for a whole range of issues. The role is as varied as the challenges and queries presented: it could be helping a family understand treatment options, helping to plan a short break, support with navigating welfare benefits entitlement, or just a friendly listening ear to validate concerns and provide reassurance.

In 2025, the team provided direct support to 5,518 people, an increase of 21% compared to the 4,546 people we helped in 2024. More than half of those cases were people facing financial difficulties. Alongside individual support, our Regional Managers and Patient Support & Advocacy Officers made valued contributions bringing patient voice and experience to NHS Renal Network activities, working with Kidney Patient Associations and attending a whole variety of information and awareness events from Truro to Aberdeen.

Working with our utility partners has meant that patients have also been supported to access information about better and more affordable energy and water tariffs, and introduced to the Priority Services Register, ensuring their particular needs are met in the event of a power or water outage. Offering truly holistic and tailored support, we are proud to be there for everyone living with kidney disease, empowering people to manage the challenges they face and enjoy a better quality of life.

5,518
individuals provided
with access to direct,
practical support

More than
13,000
individuals reached
with information and
advice





Gwilym* contacted Kidney Care UK November to see if there were any benefits he would be entitled to as he was struggling to pay his bills. After a chat, one of our Patient Support & Advocacy Officers identified that he could qualify for Attendance Allowance and discovered that his wife's PIP claim was due to expire and she was worried that she might lose it.

After helping Gwilym* and his wife complete the necessary forms and advising them that they could be entitled to more Pension Credit, we learned that the applications were successful and the couple are now in receipt of £24,417.40 per year. Gwilym* is now in discussions with our free Will writing service as he wishes to leave something to the charity as a thank you.

We're more than a £1,000 a month better off because of what you've done. We're so grateful, we wouldn't have known to claim any of this without you. It's life changing.

> Gwilym*

*Name has been changed



The Money & Energy Advice Service secured more than £1.1m in welfare benefits

Our Money & Energy Advice Service has been instrumental in reducing the anxiety of 362 households struggling to make ends meet in 2025. Supported by British Gas Energy Trust and the Vulnerability and Carbon Monoxide Allowance, our team of seven advisers have secured welfare benefits entitlements totalling £1,194,312 for patients throughout the year.

Working closely with our Patient Support & Advocacy Officers, our expert Money & Energy Advice Service provides a compassionate approach underpinned with knowledge of the impact of living with chronic kidney disease to review welfare and benefits arrangements, helping individuals navigate often complex systems to achieve the best outcomes for people who would otherwise be left to tackle these challenges alone.

The Money & Energy Advice team also use their specialist knowledge to help patients access other benefits such as the Blue Badge scheme, and local authority or regionally available grant and support schemes. They also ensure that people are on the right tariffs for utilities. Our comprehensive service is designed to empower individuals to live their lives to the full.

362

households supported

£1,194,312

secured in welfare benefits



Donna contacted us after a Managed Migration notice from Universal Credit left her worried about her finances. She was on home dialysis, waiting for a kidney transplant. Despite carefully managing her finances, Donna was finding increased energy arrears difficult to cope with.

I didn't know how I was going to pay this, and you listened, were understanding and patient so I didn't feel stressed. I am so happy I don't have to worry about this anymore.

 Donna



Our Financial Support alleviated stress and worry for more than 1,400 patients and their families

From the Charity's earliest days, our financial support has focused on making everyday life easier for people living with the challenges of kidney disease. Whether it's help with replacing a broken washing machine or help to purchase a mobility scooter, our grants make a huge difference for kidney patients with limited income.

In 2025, we awarded 1,447 grants, amounting to £693,885, to families where just a little bit of financial support can help make a huge difference. Requests ranged from cooking appliances, carpets and sheds to store home dialysis equipment to mobility scooters to restore independence. In particular, we awarded a record number of grants for household items (588), an increase of 38% over the last decade. At over £290,000, the total value of household goods we purchased for people in need was also the highest since the programme began ten years ago.



"Our grants represent more than just the item provided; they represent freedom. Freedom from worry about how to replace a broken appliance; freedom to take a break from the routine of treatment and make precious memories; freedom to get out of the house and be with family and friends; freedom and hope for the future. It's always heartening to hear about the difference the most ordinary items can make to someone's wellbeing and sense of self-worth."

Martin Plowman, Patient Grants Manager

We supported 1,447 people through our financial grants,
amounting to £693,885

Our Holiday Support, helped 1,500 patients and their families take a break

Through our Holiday Grants Service and Kidney Care UK Dialysis Freedom service, over 1,500 people were able to take a holiday in 2025. Working with our trusted travel partner Inspire, we issued 389 holiday grants at a cost of £218,715, and Kidney Care UK Dialysis Freedom arranged 1,385 dialysis bookings in the UK.

Whether people need to take a holiday, have some much-deserved respite, attend an event for work or just visit family and friends, CKD should not stop our community living life to the full. As well as support making a booking, we often give patients and UK dialysis units advice and guidance on the logistics of organising dialysis away from your usual location, the options available, funding, insurance, support that Kidney Care UK offers, information leaflets, posters and much more. It is a complicated process to navigate NHS systems, so this service really is transformational.

A record number of units positively participated in the dialysis swap scheme this year: 146, an increase of 30% compared to 2024 – which had previously been the year with the highest number of UK units participating in the scheme. We're delighted to see this and hope the growth and engagement with the scheme continues so that more people are able to take a much-needed break.

We awarded

389

holiday grants
amounting to
£218,715

Kidney Care UK
Dialysis Freedom
arranged

1,385

dialysis bookings
in the UK

“When my son started having dialysis it had a major impact on our lives and we wondered if we would ever be able to go on holiday again. We saw a poster advertising Kidney Care UK Dialysis Freedom, stating that they would make holidays not only possible, but stress free. We contacted the team and have thoroughly enjoyed our holidays every year since! Our quality of life and mental health have improved as a result and the fact that it is a free service is fantastic.

➤ Lynne and Rory



Our free Counselling Service helped hundreds of people cope with the demands of kidney disease

In a year of change for the department, we are pleased that we were able to support 267 people and deliver 1,683 counselling sessions in 2025, an increase of 9% compared to 2024 (when we delivered 1,538 sessions).

We hear frequently from people struggling to come to terms with what a diagnosis of kidney disease means to them, exacerbated by a lack of communication about their CKD from their GP. We received thousands of comments in response to our *Falling through the G-App* report about this. Here is an example of how this can affect patients' mental health: "The receptionist at my GP surgery mentioned CKD3 whilst giving me other results. I had to ask what it was; she looked it up and it eventually took five days to get through to a GP to explain what it all meant. My worrying was magnified by the fact my mother died from kidney failure."

Demand for the service remained high, and people accessing the service continued to present with significant emotional distress. Our counselling focuses on developing coping strategies, building resilience and supporting stability, contributing to improved wellbeing during times of illness and uncertainty.

In 2025 we ran

1,683 counselling sessions

supporting 267 people affected by kidney disease

Psychological support – help that addresses both the psychological and social aspects of a person's life – is vital during medical treatment, especially when patients may not feel empowered to request more time or space to make complex decisions.

Jimmy self-referred to counselling while experiencing the failure of his second transplant; he was returning to haemodialysis and preparing for further surgery before re-joining the transplant waiting list and was struggling to cope with uncertainty, anxiety and loss. Our counsellor helped him through this, and our support empowered him to ask for more time to make decisions and face ongoing treatment demands with resilience.

He later joined Kidney Care UK's Young Adult Residential Weekend at Mount Cook, describing the support as "life-changing" and "simply amazing".



Our Young Adult Service provided connection, community and confidence

Our unique community of young adults provides a valuable resource for emotional support and practical information focused on the specific needs of kidney patients aged 16 to 30. Rooted in our founding members’ philosophy of ‘For young adults, by young adults’, the community continues to grow from strength to strength with 1,290 members – 92 new members in 2025 – an increase of 8% compared to 2024.

Comprising an online community, personalised support from volunteers generously sharing their time and experience, online information webinars, and a popular residential weekend event, the Young Adult Service delivers highly valued emotional support and social interaction. Following the successful extension of our group to include 16- and 17-year-olds – young people facing the challenging transition from paediatric care to adult renal units – we looked again at our offer to ensure we are an open, accessible and inclusive community.

Repeating the hugely successful events of previous years, we hosted 63 young adults at our annual Residential Weekend, enabling them to make memories and life-long friends as well as learn new skills from cooking to climbing.



In 2025
92
young adults
joined our online
community

What Kidney Care UK has done is so amazing; bringing us all together to get away from our normal routine and into activities, share stories and just enjoy ourselves - it’s a huge relief and I hope I’m lucky enough to attend again. We are so lucky to have this available to us.

Feedback from one of the young adults who attended our Residential Weekend.


63 young adults attended our
annual residential weekend
(almost half, 43%, attending for the first time)

Our Peer Support service connected more than 200 patients; reminding them they are not alone

Having launched in 2024, our Peer Support service is now firmly established as a valued resource for kidney patients with lots of questions about what kidney disease means for them and how it may affect their lives. In 2025, we matched 214 individuals with volunteers trained and ready to share their lived experience.

We work closely with designated Peer Support Champions, often a nurse or a member of a renal unit clinical team, and peer support is increasingly being accepted as a valued part of the treatment and decision-making pathways, although most referrals are instigated by the patients themselves. Thanks to our initial partnership with the London Kidney Network, we were able to expand the service in March 2025 to include the North East and North Cumbria; we hope this will continue to grow across the UK in future.

Our amazing team of 37 peer support volunteers are the beating heart of the service, supported by two full-time staff. We have been delighted to welcome 10 new volunteers this year, providing an accessible, practical and comprehensive training and onboarding experience to maintain a high quality of support.



When Elizabeth learned her kidneys were failing and she was going to need dialysis she got in touch with Kidney Care UK for some answers and reassurance. Having spent time talking through her situation with our Support Line team, Elizabeth was put in touch with Peer Support to speak to someone about what dialysis would mean for her day-to-day life. We connected her with Shruti.

I wanted to say how wonderful my call with Shruti was. She was incredibly warm, open, knowledgeable and supportive. I learned so much from speaking with her. She made me feel truly understood and not alone in this journey. We spoke for over an hour, which really says it all.

Elizabeth



**214 people supported by
37 peer support volunteers**

Continuing the legacy of our founder by supporting children with kidney disease to live their lives to the full

Support for children and young people is central to the charity's DNA, as it was founded by a mum, Elizabeth Ward (pictured below), who was worried about the lack of support for people with kidney disease after her son Timbo was diagnosed. Our support covers a range of areas including financial grants to help when costs become difficult for family finances, support to help families have holidays and give children a break from the routine of hospital visits and access to trusted information through our national infokID patient information website.

In 2025, we also invested £14,034 supporting three children's hospital-run holidays and short breaks where staff offered young patients the opportunity to have some time away from their dialysis units and enjoy time to just be children, all the time with people who know what they are going through. We also supported 11 teams to take part in the British Transplant Games with funding of £24,298. Our financial support grants, which do not need to be paid back, helped 97 families and children at a cost of £35,679 to cover expenses such as hospital transport, holidays and short respite breaks or just the additional outlay that comes with caring for a child with kidney disease.





Providing access to trusted information when and how patients want it

2025 was a year of significant growth for the charity, and in particular growth of our patient information and digital support services. In the past, many people came to the charity with kidney failure, or approaching dialysis and needing intensive support through our financial, practical and emotional patient support services. However, more and more people are finding out they have kidney disease at an earlier stage and do not have the opportunity to discuss this with a healthcare professional. **Every single day we hear from someone who has early stage CKD and needs immediate support to understand what this means for them.**

Our digital patient information is a vital part of the way we support and empower people with kidney disease. Whether you have just found out you have CKD and want to understand what that means, you want to know what recipes you can make for your partner who has just been told to change their diet or you need help applying for Personal Independence Payment (PIP) – **we are here for you, however you need us, whenever you need us.**




Reassuring information and advice at your fingertips

The Kidney Care UK website provides clear and reassuring information for people who are searching for advice about kidney disease online. In 2025, thanks to the ongoing success of our #BloodyAmazingKidneys awareness campaign, we shared kidney health information with an incredible 2,212,635 people (compared to 1,499,645 in 2024, a 47% increase).

Our YouTube channel views were up 84% year-on-year with most of the traffic to our infoKID animation videos and our Kidney Kitchen videos about kidney-friendly lunches, snacks and comfort foods. We also produced a new charity video which highlights our mission and impact through interviews with patients, health professionals and staff. In addition, our email subscribers also grew in 2025; we sent a total of 1,837,648 individual emails to our main mailing list, a 48% increase compared to 2024.

Our social media audience grew by 23% across all of our channels, and our Facebook online support group membership increased by 13% to almost 15,000. We continue to be available to our community however they choose to engage with us, recognising that a question answered via a social media message that provides reassurance, information and support can be as valuable as any of our more intensive, personal support services.



I truly enjoyed listening and hearing Lois's story. Inspiring, emotional and a demonstration that miracles still happen!

Feedback from a Diary of a Kidney Warrior Podcast listener

Diverse storytelling and collaboration results in another great year for the Diary of a Kidney Warrior Podcast

2025 marked five years since its launch in August 2020, and the podcast continues to grow as a trusted platform for education, awareness, and lived-experience storytelling within the kidney community. In 2025, 26 episodes were released, featuring a diverse range of guests, including individuals living with chronic kidney disease and a wide range of healthcare professionals. This breadth of perspectives ensures that the podcast delivers both relatable patient experiences and credible clinical insight.


The audience for the podcast continued to grow, achieving a total reach of 23,847 (13,582 downloads and 10,265 YouTube views), reflecting an increasing engagement across both audio and video platforms. Since its launch, the podcast has achieved a combined total of 81,677 listens and views, highlighting its impact as a valuable resource for patients and families and its ability to connect with listeners on both an emotional and educational level.

Our patient information, produced through our partnership with healthcare professionals and the UK Kidney Association (UKKA), means our resources are in high demand with both kidney patients and healthcare professionals. In 2025 we sent out 389,449 leaflets – a 23% increase compared to the year before where we sent out 317,515 leaflets - from nearly 3,000 separate orders. Our literature was just as popular online, where translation and accessibility options increase the reach of our work, with 108,000 unique page views across the year.

Kidney Care UK information leaflets were requested by every main renal unit in the UK and reached much further with increased orders from satellite units, GPs, prisons, schools and pharmacies. We supplied leaflets directly to over 1,200 healthcare professionals, an increase of 54% on the previous year. Our literature is held in high regard by professionals, helping them to increase their patients’ understanding of kidney disease, and in turn, empower them to make better decisions about their care.

We added 11 new leaflets to our repertoire this year, meaning we now have 69 titles available, including four new Easy Read titles, as we seek to ensure that our material is accessible to everyone. Easy Read makes written information accessible by using short, simple jargon-free sentences with clear, descriptive images. It helps to support people with learning differences as well as those living with dementia and people for whom English isn’t their first language. All these titles are Patient Information Forum (PIF) TICK accredited, to provide reassurance of their quality to patients and professionals. Each title is written in conjunction with the UKKA through our Patient Information Committee of healthcare professionals. In association with the UKKA, we also established a new Rare Renal Patient Information Committee.

Providing patients with accessible, trustworthy and empowering information



We can’t do our job well without resources like those produced by Kidney Care UK. Our families cannot understand or move forward in the management of their condition or their child’s condition if they aren’t adequately educated.

Ellen White, Paediatric CKD Clinical Nurse Specialist



Our digital tools helped people understand their entitlements and support their applications

Our Kidney Care UK Benefits Calculator allows people to check what benefits they are entitled to in a way that suits them. In 2025, 4,831 people completed a Benefits Calculator calculation, helping households identify £653,928 in potential unclaimed benefits.

Our complementary digital tool, the PIP Helper, offers step-by-step guidance from our Patient Support & Advocacy team for people who are applying for PIP. Our PIP Helper had 3,775 users in 2025 and we also launched an equivalent for Scotland, the ADP Helper.

Our *Kidney Matters* magazine continued to inspire, educate and inform

In 2025 we sent 59,115 copies of our magazine *Kidney Matters* to individuals, with copies also sent to more than 280 hospitals across the UK. The number of people signing up to receive a copy grew from 13,300 to 16,750 by the end of the year, an increase of 26%.

Our autumn issue of *Kidney Matters* included an interview with Spudman (Ben Newman), who is almost as well-known for his brightly coloured pink mohawk as he is for his jacket potatoes. This Tamworth-based spud seller and TikTok sensation is a generous, larger-than-life character with a huge online fan base avidly following his daily antics. Ben's interview resulted in the number of people reading our autumn issue of *Kidney Matters* online increasing to 6,500!



Our Kidney Kitchen provided recipe inspiration for tens of thousands of people

In 2025 12,888 Kidney Kitchen recipe collection magazines were ordered; this means that to date 52,218 copies of our five Kidney Kitchen magazines have been ordered since we began to produce them in 2022. They continue to be offered to patients free of charge.

During 2025 our range of Kidney Kitchen recipe collection magazines expanded to five titles. In July we released *African and Caribbean Recipes* – a collection of kidney-friendly, traditional recipes and diet advice created to support our patients and their family and friends. This title joins our previous issues: *Eat Well Spend Less*, *Safe Weight Loss*, *South Asian Recipes*, and *Classic Recipes*.

As well as our range of magazines, the Kidney Kitchen website continues to grow and provide recipe inspiration for thousands of people looking to eat well with kidney disease. The Kidney Kitchen website had 456,00 unique users in 2025 (an increase of 21% compared to the year before when we had 378,000 unique users) and we now have 275 recipes for people to follow online.

My mum has stage 5 CKD and we're doing all that we can to prolong the time before she'll need dialysis, including changing her diet. The recipe magazines I got her from your website have been an inspiration for her to start cooking a dish or two a week and have been a great success. Her current potassium and phosphate readings are almost normal and her eGFR readings have rallied a bit. It's amazing to see the effect that controlling diet can have.

Beth, daughter of Elaine with stage 5 CKD

Working in partnership to improve health and care services across the UK

Many patients have told us that they see us as a vital part of their lives, for everything medical you have the NHS but for anything else, you need Kidney Care UK. We recognise that for us to deliver real change we also need to work with our colleagues in the NHS and in social care to provide equity of access to the highest quality services for everyone, and empower patients to become partners in their own care and take more control of their lives.

Whether this is investing in system change by transforming the care provided to patients, partnering with organisations across the kidney community to drive service improvement, giving patients a voice and supporting them to become more involved in their own care or sponsoring teams to take part in the Transplant Games, we are here to work with others to improve kidney care for everyone no matter where they live, how old they are or at what stage of their kidney journey they are.

Giving patients a voice and a choice, empowering them to be partners in their own health care.

Improving home therapy rates through the national DAYLife project

Only 17% of people who could benefit from home dialysis are actually accessing this as a treatment for their kidney failure. Giving patients a choice of the right treatment for them is vital in terms of patient engagement, empowerment and confidence but there are still parts of the UK where rates of home dialysis are very low, and that patient choice and support for this treatment is simply not available.

As a result, we are working in partnership with the UK Kidney Association, Fresenius Medical Care and the National Kidney Federation to promote home therapies and help units achieve a minimum of 20% of their patients on home dialysis. The DAYLife project (Dialysis at Yours, Life Fulfilled) was established in 2022 to promote equitable access to home dialysis across the UK.

The DAYLife Knowledge Hub website has now become a key resource for healthcare professionals, helping teams champion home therapies and collaborate on best practice. Through a series of webinars and in-person events for both patients and healthcare professionals, progress continues to build across the four workstreams:

- **Shared Decision Making** – clinical practice guidelines are in discussion
- **Psychosocial Support** – a new training module was launched in December, with initial data showing 582 people had started the training
- **Peer Support** – Peer Support Champions established and paper presented at UK Kidney Week
- **Shared Haemodialysis Care** – a Shared Care Patient Charter is being developed and tested.

“ There is space for significant growth in home therapies across the country and great efforts are being made to do this.
Feedback from the DAYLife summit held in Birmingham in September

Empowering patients to take more control through the national Shared Care programme

Patients have told us that when they feel more involved in their care it gives them more control, makes them feel more confident and builds self-esteem. Improving people's experience of haemodialysis through a leadership change in approach and attitude is at the heart of this innovation which has been recognised by the Royal College of Nursing as an exemplar of person-centred, quality care.

Kidney Care UK is into its second year of hosting Shared HD Care, having supported the programme financially since 2017. The focus in the last year has been to provide equal opportunities for patients across the UK to access shared care as a benefit in itself or as a stepping stone to home haemodialysis.

In 2025, **19 haemodialysis unit teams** engaged with programmes developing patient empowerment through Shared HD Care training, **involving 50 staff and 21 patients and carers**. We ran two manager focused training sessions which led to 42 managers receiving training and **242 staff attended five themed community of practice forums** to maintain momentum of their improvement work.

Topics have included learning about teaching self-needling, communication techniques and presentation of patient information leading up to a national noticeboard for shared care competition. We **ran 11 patient focus groups**, keeping a core group of patients involved and sharing their perceptions of care to support the learning. This means that **over 1,000 staff have now been trained in shared care** through the face-to-face and virtual courses.



At first, shared care felt overwhelming, however, the outcome has been incredibly positive. Patients are excited and happy, looking forward to their next session.

Staff member

It is very reassuring to see how committed staff are to a holistic approach to patients' wellbeing.

Kidney patient



Record number of responses received to the Kidney Patient Reported Experience Measure (PREM) survey

The Kidney Patient Reported Experience Measure (PREM) survey puts patient experience at the heart and forefront of driving service improvement in the NHS. The 2025 PREM marked our tenth annual survey, delivered in partnership with the UK Kidney Association (UKKA) and supported by the University of Hertfordshire. Conducted over eight weeks in autumn 2025, the survey invited patients to rate 13 key themes on a seven point scale and to share personal feedback about their care.

This year saw a record 17,340 responses, the highest participation to date. Among the thematic scores, privacy and dignity received the highest ratings, while transport scored the lowest, which has been the case for several years, and continues to drop. Beyond tracking experiences over time, it is essential that the insights collected lead to meaningful action. The “you said, we did” posters we supply encourage units to display their results to demonstrate how patient feedback is actively shaping improvements in care.

In 2025, a record **17,340**
patients completed our PREM surveys

When discussing how useful the PREM was in highlighting their patients' views of shared decision making at the unit, the Renal Matron at Reading explained:

“We came together with a joint vision and goal to engage patients in shared decision making and improve our understanding of what was important to haemodialysis patients. In 2024 we completed this work and this is now embedded in our practice and monitored at clinical governance.”



Investing in a major national change programme to transform Advanced Kidney Care Clinics

In the UK there are around 30,000 people on dialysis, and as people approach kidney failure, the thought of facing treatments like dialysis and/or a kidney transplant can be incredibly overwhelming. At Kidney Care UK, we exist to ensure that anyone facing kidney failure has all the support they need, at the earliest point after diagnosis, to make decisions about, and have access to, the best quality of care and treatment for them as they take on the next part of their kidney journey.

The Advanced Kidney Care (AKC) Clinics project, Transform AKC, run in partnership with the UK Kidney Association, is now in its second year. The project aims to improve equity of access to the highest quality care and drive system-wide, sustainable change in the support and preparation of patients who number around 20,000 across the UK as they approach kidney failure. A multidisciplinary AKC working group has been formed to harness the collective knowledge of AKC clinical leads across the UK, and five pilot sites (Bradford, Kilmarnock, Nottingham, Royal Free London and Lister Stevenage) have been recruited as part of the quality improvement programme to pilot change ideas on the ground.

Individual projects are underway, the learnings from which will help create best practice guidelines to standardise care across AKC clinics nationwide. The project has a patient advisory group, with representatives from the pilot sites and wider community of practice that has been established to champion change. Workshops at webinars, face-to-face summits and group working throughout 2025 have identified best practice ideas to standardise information provided to patients at their first AKC appointment.



Giving healthcare professionals and kidney units our support to help improve care

Kidney Care UK has a long history of working collaboratively in partnership with healthcare teams and in 2025 this was no different. **We awarded 28 grants, totalling £67,695**, to enable healthcare teams to make localised care improvements for their patients. These included financial support to help young people transition to adult services; kidney patient information days; short breaks for children with kidney disease facilitated by their nurses and doctors; and gifts for people in units over Christmas. We also provided financial support to the British Dietetic Association and the UK Renal Social Worker group.

Our funding for these activities is provided over a number of years, so **our grants to support healthcare partners reached £254,219 in 2025**. That means in total we provided more than £300,000 in support for patients in this way across the UK this year.

Representing the patient voice and campaigning for change

The patient voice is at the heart of everything we do. It is the most important part of our work to influence and campaign for changes in policy and practice. We're fortunate to have many people willing to share their perspectives and experiences of living with kidney disease and kidney failure. These people include patients, carers, family members and living kidney donors. Their insights are critical, providing credible and authentic insight that shapes and informs our work.



"There has never been a more important time to ensure the voices of the kidney community are heard. With cuts to statutory funding, proposed changes to welfare benefits and a lack of capacity in the healthcare system we need to take action for the thousands of people whose lives have been turned upside down due to kidney disease. Because the transplant waiting list is the longest it has ever been, now at a 10-year high, we need to call on the government to ensure that any changes, developments and improvements to the health system in the UK consider the needs of people with kidney disease."

Fiona Loud, Policy Director

Ensuring kidney disease is on the political agenda

During a time of big change and development in the NHS, we continue to work tirelessly to get CKD on the UK political agenda. In May, we convened an expert parliamentary roundtable where we discussed the importance of the early identification of kidney disease and widely shared a report capturing our recommendations for change.

We were very grateful to Dr Simon Opher MP, who was inspired to support the charity and who worked with us to send an open letter to health leaders, supported a joint kidney community petition calling for a national kidney strategy (signed by over 13,000 people) and sponsored our parliamentary event held with Blood Pressure UK in December. Our fantastic kidney campaigners have also been invaluable in raising political awareness of kidney disease, writing to their MPs, signing petitions and attending our parliamentary events.



Thank you again for hosting such an important event today. I had the chance to speak with one of the attendees who shared his experience of being on dialysis. It was incredibly moving to hear his story, and I'm grateful you brought together so many powerful voices and experiences.

➤ **Kim Leadbeater MP, who attended our Parliamentary event hosted with Blood Pressure UK in December**

Championing the issues that matter most to our kidney patient community

We are constantly ensuring that the issues that matter most to our community are represented through our work. We do this through our Patient Advisory Group, regular insight gathering via our Support Line and Patient Support & Advocacy teams, as well as our online community and our Kidney Care UK campaigners' network.

Our Patient Advisory Group in particular had a very active 2025. Comprised of a diverse group of patients from across the UK, it represents a mix of treatment options, ages, and people from different ethnicities, communities and backgrounds. This year, the group provided the trusted patient voice on a range of topics including: a workshop session on the NHS 10-year plan, discussions on improving patient safety for people with kidney disease, feedback to help shape the charity's organisational strategy, and engagement in our work in calling for a modern service framework for CKD.



It has been a pleasure to be a part of the Patient Advisory Group. It does wonderful work and to be invited to contribute for the benefit of patients and the charity is a continued privilege.

Dan Rennie

Working to represent patients from all nations of the UK

Our work in Scotland has included contributing to government consultations, feeding into a government debate on CKD and meeting with the government on issues including dialysis transport, psychosocial support and CKD prevention and early detection. We worked directly with the Scottish Government to increase flu and Covid-19 vaccination uptake, featuring in their communications to explain why people with CKD are vulnerable to these conditions.



As a result of our response to the Northern Ireland Public Health Agency's consultation on their Corporate Plan we secured the first ever recognition of their duty to promote organ donation in Northern Ireland. Their plan now includes the aim to "improve public awareness and understanding of organ donation and transplantation, and the change in legislation on consent, encouraging positive actions and behaviours in relation to organ donation across society".

We were delighted to end the year having confirmed the recruitment of a joint Policy Officer for Wales, employed by both Kidney Care UK and Kidney Wales. Anny, who joined us in early 2026, will play a vital role in ensuring the voices of kidney patients in Wales are represented. We're always keen to collaborate with other organisations for the good of people living with kidney disease and look forward to our relationship with Kidney Wales achieving great results for Welsh kidney patients in the future.



Welfare reform proposals halted

In March 2025 the *Pathways to Work: Reforming Benefits and Support to Get Britain Working Green Paper* set out the government's proposed approach to welfare reform. It included changes that risked removing essential financial support from significant numbers of people with CKD.

In order to develop an evidence-based response to the consultation proposals that was deeply rooted in the voices of people with kidney disease, we undertook an online patient survey and discussion groups with Kidney Care UK patient services, receiving more than 500 responses. Our results suggest tightening PIP eligibility may have unintended consequences of reducing access to work. We shared our results with government, who have halted the planned tightening of PIP eligibility for now, and we will also share them with the ongoing government review of PIP.

World Health Organisation puts kidney disease on the map

In May 2025 the World Health Assembly (WHA) formally adopted a resolution on reducing the burden of kidney disease. In December this was followed by a United Nations political declaration on long term conditions, which also includes CKD. The presence of kidney disease could lead to its prioritisation for every government, including funding and programmes of work; it was an important addition that was missed in the first draft.

We worked with the UK Government to support the inclusion of CKD in the declaration, we hope they will therefore be encouraged to prioritise a national kidney strategy. We are proud to have spoken on behalf of UK patients at two side meetings of the WHA and co-signed an open letter calling UN Member States to support the inclusion of kidney disease in the Political Declaration.



Psychosocial support for all people with kidney disease must be part of NHS future plans

Improving support for patients dealing with the social and emotional impact of kidney disease remains at the top of our policy agenda, with much of our work led through our role chairing the National Psychosocial Working Group (NPWG). In June, we published our *Left to get on with it: The real impact of inadequate psychosocial support in kidney care* report which presented the findings of a UK-wide survey of 1,796 adults with CKD. The report revealed the significant social and emotional toll of kidney disease and highlighted that psychosocial support for people with kidney disease in the UK is urgently needed and currently lacking.

More than 8 out of 10 (81%) of respondents told the Charity that they needed kidney-specific emotional support from their kidney team, but are unable to get this. Almost half (49%) said that they had never been asked about their mental health by their kidney doctor. One of the respondents told us:

I can't cope.... I don't know what to eat, I'm sick most days physically, and mentally I'm exhausted and ready to give up, the only reason I'm still alive and have got this far is because I have a child, otherwise I would have taken my own life months ago.

We have used these findings in talks with government to ensure that they know that targeted and specialist psychosocial support for all people with kidney disease, at all stages of CKD, must play a prominent role in the healthcare policy plans and guidelines of government, health boards and health trusts in the UK.



A #BloodyAmazing year for our awareness and prevention campaign

2025 was a monumental year for our national #BloodyAmazingKidneys campaign, as we work tirelessly to raise public awareness of kidney disease and campaign for early identification and better disease prevention. **By the end of the year, we had secured just shy of 275,000 completions of the Kidney Health Checker on our website from individuals taking action to check their kidney health.**

In March, we presented the #BloodyAmazingKidneys campaign at a Behavioural Science and Public Health conference in Liverpool. In a busy week centred around World Kidney Day, we also achieved a significant piece of media coverage in the *Daily Mail* as well as in *The Mirror*. This coincided with a day of kidney health awareness at Southampton and Portsmouth hospitals where more than 500 people learned about the campaign while having an on-the-spot blood test to check their kidney function.


We presented the #BloodyAmazingKidneys campaign at the UK Kidney Week conference in June. On the same day, the campaign won a Boehringer Ingelheim Global Patient award for innovation and awareness. The following month we learned that we had successfully been awarded the JCDecaux Community Channel Partner in October, which led to billboards and bus stop adverts featuring the campaign appearing at hundreds of sites across the UK.

In November, our abstract on the campaign was accepted as a presentation at UK Kidney Week 2026, and we also had a poster submission accepted to the Diabetes Professional Conference in Liverpool at the end of April 2026; all fantastic opportunities to raise awareness of the campaign and kidney disease.

In December, we launched our *Falling through the G-App* report which built upon the work of our policy team and our #BloodyAmazingKidneys campaign to highlight the poor experiences of individuals discovering their diagnosis of kidney disease via the NHS App. The report secured national media coverage in the *Daily Mail* and *The Daily Telegraph*, and we heard from hundreds of patients who told us that they'd had similar experiences. We've used these findings to engage with the NHS team responsible for the NHS App and are in discussions about how we can stop people from finding out about their kidney disease in this way without the support they need to understand what it means for them.

"I was given my diagnosis over the phone by my pharmacist when I was out shopping. I was devastated. It turns out I was diagnosed seven years earlier but no one thought to tell me."

Across the year we spoke at many meetings with NHS groups, kidney networks and ICB meetings as well as sessions with partners about the campaign. This led to support from various groups, including GP surgeries showing animated adverts for the campaign on their TV screens and messaging sent out to patients via healthcare groups. With more exciting plans to get the #BloodyAmazingKidneys campaign out into the world in 2026 and beyond we are incredibly grateful for everyone who has supported and shared the campaign so far.



Managing our charity effectively and efficiently

Ensuring Kidney Care UK is well run is critical to the way we deliver as a Charity. We make sure our staff are inspired so they can deliver excellent support for our community, we ensure that personal data entrusted to us by patients is safe and secure and we work as efficiently as possible so that every pound we receive from our generous supporters is spent wisely. Together this means we can remain the Charity our community needs.


With the continued growth of the Charity in 2025, the need to ensure we are a well-run Charity as well as a Charity “worth giving to” remains a top priority.

Data and IT infrastructure giving supporters reassurance

In 2025, we continued focusing on keeping our systems secure and working more efficiently, helping us make the most of every pound raised for the charity and ensuring that all the data we hold about our beneficiaries stays safe.

The launch of a new database, Beacon, had the biggest impact on our workforce, with a huge amount of work undertaken by all involved leading to its launch in March 2025. As a result, we are already seeing reduced manual administration and improved efficiency and data reporting. This plays a major role in our digital transformation plan to move the organisation to a fully cloud based operation by the end of 2026.

We renewed our Cyber Essentials accreditation in 2025 following updates to our systems, giving reassurance to those sharing information with us that we have the appropriate systems in place to keep their data safe. We also conducted comprehensive penetration testing. This proactive, independent assessment by Cyber Arm Security ensures that our defences remain resilient against evolving cyber threats, and patient data entrusted to us remains safe. In 2025 we also commenced and completed a programme of work to update or upgrade our computers to Windows 11 to ensure stability, integrity and security of our systems, well in advance of the October 2025 Microsoft end of full support cut-off date.



Following the implementation of the Beacon database we are seeing significant improvements to efficiency and data analytics. Here's what Ellen Hill, our Support Line Leader has to say:

The implementation of Beacon has strengthened the effectiveness and efficiency of our Support Line service. The platform enables the Support Line team to quickly record details of patients and their loved ones, while providing access to their history and previous contact with Kidney Care UK.

Looking after our people

At Kidney Care UK we know that are people are our most valuable asset. It is through their commitment, dedication and passion that we are able to ensure we always go the extra mile to support patients and their families.

During 2025, the organisation experienced yet another year of growth, transition and consolidation across the workforce. Headcount rose during the first half of the year before settling to around 112. This represents a growth of over 280% in staff over the last five years, allowing us to respond to the significant increase in demand for our Support Services.

Progress was made in modernising our core HR processes, including the roll out of a new payroll system, and updating our DBS police check and occupational health service provider. The take-up of apprentice qualifications funded from the apprentice levy has continued to see several of our staff learn new skills and knowledge which they are sharing with colleagues in the areas of marketing and coaching.

Our staff benefits scheme continues to be used by our team, including health cashback for dental or flu vaccinations, as well as mental health support to improve wellbeing. Our employer pension scheme has been enhanced with the roll-out of a new staff app to help our team keep track of their pension investments.

In 2025 we had
112 members of staff
an increase of over 280% since 2021




“
When looking for my next role within the charity sector, I knew I wanted to be part of an organisation that directly supports beneficiaries. Since being warmly welcomed into the Kidney Care UK family, I have learnt just how important our work is and I feel privileged to know that I, and my team, make a tangible difference in ensuring that no one faces kidney disease alone.

Rachel Paisley, Head of Fundraising

Thank you to our generous fundraisers, donors and supporters

Thanks to our incredible supporters, 2025 has been a year of generosity and growth. Every donation, no matter the size, has helped transform lives of people affected by kidney disease. With your support we raised just over £5,000,000 in 2025, an increase of 29% compared to the year before.

Our work would not be possible without you, and we are so grateful, thank you!



In 2025, our fundraising income was

£4,374,487

(up 30.5% from £3,350,776 in 2024)



Gifts ensuring our support is there for years to come

This year, more people than ever have chosen to stand with us by giving regularly. Supporting Kidney Care UK in memory of those we have loved and lost remains a powerful way to celebrate and honour those who have lived with kidney disease, and we are hugely grateful for the £132,750 donated in memory of a loved one, bringing hope and support to others.

Gifts in Wills continue to play a vital role in ensuring we can plan our services with more certainty for years to come. In 2025, we received £400,791 from gifts in Wills, a testament to the generosity of those who want their kindness to live on for future generations. Our largest legacy in 2025 was worth over £150,000; a truly life changing amount.

In addition to these kind and generous donors the number of people donating monthly to the charity almost doubled with the launch of the Kidney Care UK Lottery in July 2025. In just six months we sold over 20,000 lottery tickets to 427 people.



From mountains to mosaics, our fundraisers continued to astound us with their challenges

Have you ever considered trekking Mount Kilimanjaro, climbing the three peaks, or skydiving 15,000ft? Well, those are just a few examples of the incredible feats that our 162 #KidneyWarriors completed. Across our charity place events, our runners covered more than 5,000 miles between them, a phenomenal achievement for both our supporters and the team behind them, cheering them on every step of the way.

For 130 of our supporters, running the TCS London Marathon for Kidney Care UK was their goal, and not only did they do it, but they went above and beyond. TCS London Marathon 2025 wasn't just a record breaker for them but also for us, with our largest team to date and our biggest ever single fundraising day in our history. In total across all of our combined challenge events, a remarkable £762,435 was raised to help fund our work helping kidney patients and those affected by the condition across the UK.

Katie who has polycystic kidney disease took on the incredible feat of running the TCS London Marathon for us.

“While I’m still fit and healthy, I wanted to do something that pushed me, so that if I am poorly in a couple of years’ time, I can look back and think ‘oh I did that, it was amazing!’”



Our wonderful community supporters contributed £275,086 – another record-breaking total for the charity. Their efforts never fail to amaze us. Supporters from across the UK took part in their own fundraising activities, including trekking tube stations wearing weighted vests, to hosting bake sales, to a mosaic tile painting evening, knitting sessions, tribute nights, coffee mornings and cake sales. There were so many creative, memorable and heartfelt ways that people chose to support us in 2025.



I sadly witnessed first-hand the effect of kidney failure on my mum; she is waiting for a transplant but in the meantime a dialysis machine keeps her alive three times a week. Kidney Care UK have supported both my mum and me more than they could ever know and for that reason I decided to ask six friends (all of us 16 years old) to join me on a mammoth challenge, to solely navigate and climb four of the tallest mountains in England in one day, including the tallest in England, Scafell Pike at 978m high. We smashed it in 6.5 hours!

Seb Murphy



Our Taste of Cornwall event with our Chef Ambassador Nathan Outlaw was an unforgettable evening of great food raising vital funds for our work. The team whipped up a four course feast of local Cornish produce, and freshly caught fish, and the night was a wonderful celebration of the kidney community in the South West who danced the night away to the sounds of the Motown Pirates.

In Northern Ireland we saw two spectacular events come to life: a glamorous Gala Dinner at Titanic Belfast to celebrate our 50th anniversary, and the ever popular Golf Classic event hosted by BBC presenter Stephen Watson. These events were attended by more than 500 guests and brought together the Northern Ireland kidney community. More than £86,000 was raised through these events – a significant amount that is helping to change lives across Northern Ireland.



"One of the reasons I am so proud to work for Kidney Care UK is knowing that we're providing support to people who really need it and we're doing it now and for the future. As a charity, we are not just talking about the problem – we are providing practical and tangible solutions to those facing immediate crisis, now and forever. I'm always so touched to hear about why people are supporting the charity and it's really struck me in the last few years how many more people we are seeing with kidney disease fundraise for us."

Laurie Cuthbert, Director of Fundraising, Marketing and Communications

Building partnerships that add real value

In 2025 all of our existing corporate partners renewed their support of Kidney Care UK and through their generosity we were able to raise almost double the previous year's figure, at £2.25m, representing a 86% increase compared to 2024. We were particularly delighted that all of these partnerships have evolved from single-year partnerships to multi-year relationships, with partner staff joining us on visits to dialysis units to talk to patients directly and experience first-hand how we help kidney patients thanks to their support.

We continue to strengthen relationships with energy and water providers working collaboratively to educate, train and inform their working practices, such as the importance of kidney patients being on the Priority Services Register and accessing affordable tariffs, ensuring that they can provide vital tailored support for thousands of people in their regions with chronic kidney disease. Five years ago, our income from corporate partnerships was non-existent. We have recognised not only the role that these relationships can have in terms of funding our vital services, but also in raising greater awareness to educate more people about the devastating impact that kidney disease can have.

In addition to funding, many organisations are working with us to improve their support for people living with chronic kidney disease, including creating dedicated support lines and greater accessibility to medical tariffs. We support all our corporate partners with bespoke training, highlighting what our community tell us what living with chronic kidney disease is like and how it might impact energy, water and communication needs – this has been critical in building a greater awareness of the reality of chronic kidney disease for employees of many utility companies across the UK. Working in partnership in this way with many organisations means that we can provide more support for people living with kidney disease and ensure diverse experiences are represented.

Despite a challenging fundraising landscape, we are proud to have deepened our Trusts and Foundations relationships with our current funders and to have welcomed new supporters to our Kidney Care UK family. Trusts income has grown by 35% over the year to £305,828. We value the support of every Trust and Foundation we work with and over the coming year we are looking to strengthen these relationships further, focussing on developing more long-term partnerships.





Our fundraisers raised
£4,374,487!



£2.3m

raised through our
corporate
partnerships



More than

£400,000
from gifts in Wills

Our largest legacy in
2025 was worth over

£150,000

£762,435

raised by our
challenge events
team!



The number of people donating
monthly to the charity almost

doubled in July 2025

In 6 months we sold over



20,000

lottery tickets to 427 people

5,000 miles

= the distance our runners covered across the year!



11km of wool
used to knit 64 woolly hats
for the dialysis patients at
Basingstoke dialysis unit

£305,828

in support from Trusts and
Foundations



Our community
supporters
contributed

£275,086



Over

720 miles

were covered by
people
(and their dogs)
through our October
Dog Walk challenge!

Looking ahead to 2026: our aims and goals

- We will continue to extend our reach and engagement across the UK, so all patients are aware of the Charity and are able to access our support, with a focus on increasing our profile in the devolved nations and underserved communities.
- We will review all our Patient Support Services seeking to deliver excellence across all service design and quality standards, ensuring best-in-class support that meets patients' needs.
- We will continue to lead, in partnership with healthcare professionals, on a national programme to improve Advanced Kidney Care Services, ensuring that all patients receive the highest quality of care and are aware of the holistic support available at the earliest point on their kidney journey.
- We will continue to prioritise supporting our staff with a clear focus on wellbeing and development. Working with HR, managers and our Staff Engagement Group, we will develop and implement an employee wellbeing plan, a structured approach to management training and personal development, and conduct a review of our core values and behaviours.
- As part of our digital transformation plans, we will continue to learn how to use our new CRM database well and reduce manual administration for our staff and we will review our telephony and data storage capability as we progress our journey towards a fully cloud based operation.
- We will review and refresh our five-year strategy, to ensure we remain focused on those issues and themes that are of the highest importance to kidney patients and where we can make the greatest difference to the quality of patients' lives.
- We will conduct a full strategic review of our partnerships and hospital grants programme to ensure it remains aligned with the Charity's core aims and targeted where we can make the biggest impact on the quality of services and patient outcomes.
- We will continue to raise our profile and levels of support and engagement in Scotland, Wales and Northern Ireland, so we are assured our approach is fully aligned with a truly UK patient charity.
- We will continue to work to increase the power of patient voice and involvement, with a particular focus on our Shared Care, Home Therapies and PREM programmes so that true patient choice and empowerment allows more patients to take control of their lives and be partners in their own care.
- We will continue to deliver and campaign for universal access to high quality psychosocial support through our position as Chair of the National Psychosocial Working Group, ensuring that our Manifesto underpins clinical thinking in this area.
- We will continue to expand our patient information and education resources, packaging our information

around patient pathways, key lifestyle and quality of life domains and ensure that patients can get the information they need, when they need it and in a format they choose. This will be supported by the development of a digital education platform to support access to greater digital information.

- We will continue to ensure that patients' views are effectively represented, and their voices heard at the heart of policy and practice in the UK nations and continue to develop our campaign to increase the rate of early diagnosis and prevention for individuals at risk of chronic kidney disease.
- We will continue to develop our Peer Support service into a national service in partnership with renal healthcare organisations, seeking to create a volunteer village ethos in the Charity and grow volunteer numbers.
- We will inspire more people to support our work and grow our fundraised income, with a target to raise £5m in 2026 so we can support more families affected by kidney disease and meet the increasing demand for our services.



Our finances: financial review of the year

A year on from the Charity's largest period of expansion, 2025 was a year of embedding the growth achieved, whilst improving the service delivered to patients and upgrading the Charity's processes and systems. Staff numbers remained stable at approximately 112, reflecting a conscious pause in expansion while we focused on strengthening delivery and quality across our services. The Charity continued to build on improvements made to services, supported by a more diversified income generation base. Total income for the year was £5,040,719 (2024 £4,123,556), representing an increase of 22%, while total expenditure was £6,686,172 (2024 £6,713,589) reflecting ongoing cost of delivering an expanded service. The Charity benefited from net investment gains of £617,383 (2024 £2,144,359). Overall, this resulted in a net negative movement of funds of £1,028,070 (2024 -£445,674).

Income generated increased across a number of income streams, with corporate and event income performing particularly well, whilst we saw a reduction in income from legacies. Income generated after excluding investment and legacy income increased by 54% to £3,973,697 (2024: £2,581,156), this figure includes £1,670,544 (2024: £941,285) income from charitable activities and merchandise sales of £53,503 (2024: £47,954). This continued uplift reflects our strategic objective to support more patients and expand our income streams. Notable funded projects include the Advocacy & Patient Services expansion (Safe and Warm; funded by our Gas Distribution Network Partners: Cadent, SGN, Wales and West Utilities and Northern Gas Networks) and the Money & Energy Service (funded by the British Gas Energy Trust).

Overall, our charitable activities expenditure remained broadly in line 2024, totalling £5,600,735 compared to £5,664,702 in the prior year. We continued to experience an increased need for direct, one-to-one patient services, such as advocacy, money and energy advice and counselling. This is understandable in the context of the ongoing cost-of-living crisis and the expansion of our service reach and awareness during 2025. This expenditure is aligned with our strategy to improve the way kidney patients are cared for across the UK, ensuring access to the highest quality holistic care. We also continued to ensure that kidney patients had access to the most accurate, up-to-date patient information, both in hospitals and online.

We continued to invest in our fundraising capability to sustain and grow our fundraised income over the long term. This remains closely aligned with our strategic aim to inspire more people to support our work, drive income growth and develop a mature and resilient fundraising portfolio, enabling us to better meet demand and support our beneficiaries. We have seen results from this investment, with income increasing notably, particularly non-legacy income which performed especially well. Expenditure on raising voluntary income increased by 9% to £1,012,171 (2024: £927,384) reflecting the development of our fundraising capability.

As of 31 December 2025, our funds totalled £26,053,702 (2024: £27,081,772), of which £25,434,709 (2024: £26,688,763) were unrestricted. Restricted funds totalled £527,833 (2024: £297,316) and endowment funds £91,160 (2024: £95,693). Of the unrestricted amount, £25,000,000 (including tangible and intangible fixed assets with a net book value of £458,205) is held as a designated fund to deliver our grant-giving programmes in perpetuity; the balance of the unrestricted funds represent free reserves

which stood at £434,709 (2024: £488,763). The Trustees agreed that a transfer of £1,200,000 be made from the designated fund to the general fund. The transfer was made to off-set the impact of the in-year deficit; the Trustees believe this represents an appropriate level of funding to generate sufficient income to cover regularly occurring grants and running costs of the Charity.

The Trustees have an aspirational designated fund reserve policy of £30,000,000. The Trustees acknowledge that the current balance of £25,000,000 is below the aspirational target, reflecting both fluctuations in investment markets and continued investment in the Charity's growth. The Trustees remain satisfied that the £30,000,000 target is both appropriate and attainable. The Trustees are content that current reserves levels are sufficient.

Investment policy and performance

At the end of the year under review, the Charity's dual investment portfolio was managed by Cazenove Capital Management and CCLA Investment Management Limited (CCLA), broadly split equally between the two managers. The Charity's small Endowment Fund is also managed by CCLA. The portfolio structure combines actively managed approach through the CCLA COIF Fund and with a passive investment mandate operated by Cazenove, providing diversification of the Charity's investment risk profile. The Investment Managers operate with full discretionary powers within certain agreed restrictions and limitations, as delegated by the Trustees, and they report regularly to the Finance and Investment Committee. The Finance and Investment Committee and the Trustees continue to be supported by independent advice from Enhance Group (UK) Limited, based in Jersey.

During the prior year, on behalf of the Trustees, the Finance and Investment Committee (the Committee) undertook a competitive tender of the investment portfolio and managers, with the assistance from the Charity's investment advisors. The Committee carried out the review during May and June 2024 and put their recommendations to the Board in June 2024. The tender was underpinned by the following evaluation criteria: Performance, Process, People, Planet and Price. After concluding the tender, the Trustees agreed that the Charity should retain Cazenove Capital Management and replace Evelyn Partners Investment Management LLP with CCLA Investment Management Limited, investing in their COIF Charities Investment Fund (COIF Fund). The removal, appointment and onboarding process started in July 2024 and was fully complete by November 2024.

Macroeconomic conditions were broadly supportive for investors, with inflation cooling in many countries and the easing of interest rates by many central banks. Global equity markets performed well resulting in an increase of circa 5.5% of funds under management, amounting to a £617,383 gain (2024: £2,144,359 gain). Although the overall performance of the portfolio was positive, this was primarily driven by a strong performance by Cazenove of full-year return of 12.7%, by comparison CCLA had a challenging year and the portfolio returned -1.9%, well behind the return benchmark of CPI + 4%. The Trustees understand that global markets are likely to remain volatile throughout 2026 and individual investment manager performance will continue to be closely monitored.

The investment objective is to achieve a long-term total return in excess of UK inflation, through a combination of growth in capital and income derived from a diversified portfolio of investment assets with a moderate risk profile. As of 31 December 2025, the Charity's investments were 69% in equities, 13% in fixed interest, 15% in property and alternatives and 3% in cash.

Kidney Care UK's investment policy stipulates there should be no direct exposure to tobacco stocks.

Reserves policy

The Trustees have reviewed the Charity's reserves requirements in line with the guidance issued by the Charity Commission. Looking ahead, the Trustees anticipate that there will be significant increase in demand for people affected by chronic kidney disease. This is driven by changing demographics, the rising incidence of renal failure as a proportion of the population in the UK, and ongoing pressures on government funding for the NHS.

Within the parameters of its current policies, the Trustees expect to be able to meet the needs for financial support of patients and their families for the foreseeable future. The Charity also expects to be able to sustain its support for, professional, clinical and social carers, the development of services and facilities, and the provision of equipment and service improvement initiatives for the better treatment of kidney patients and their families, and research into the effectiveness of those services and provisions.

Kidney Care UK readily re-deploys elements of its investments to fund posts, projects or research or to support cashflow requirements. The Charity relies on investment income and capital appreciation to fund day-to-day expenditure in furtherance of its primary charitable objects and continues to invest in its growth and transformation, in pursuance of improving the quality of life of kidney patients. Without this investment income, the Charity would be unable to deliver the level of support required by its beneficiaries, as such, Kidney Care UK is not at liberty to deploy invested funds elsewhere without compromising the future delivery of its primary objectives. The Charity's free reserves stood at £434,709 as defined in the Charities SORP, which represents about one month of expenditure. The Charity's investments will therefore remain an essential source of income to meet its charitable objects and may be drawn down as needed.

The Charity has set aside a core designated invested reserve fund, the income and capital appreciation of which, together with voluntary donations and income arising from other activities, will for the foreseeable future provide for the administration of the Charity, the needs of our "Objects", and the depreciation of the purchasing power of resources by inflation. In addition, the Charity will seek to retain sufficient surplus resources to mitigate against the inherent volatility of holding investments. The reserves policy and level of the core investment funding is reviewed annually by the Board. Resources in excess of the Designated Reserve are retained as a General Reserve, which the Trustees will seek to apply appropriately over the short term.

Going concern

The economic uncertainty caused by the changes to US trade tariffs, the ongoing war in Ukraine and the in the Middle East does pose risk to the short-term value of investments in 2026. However, our approach remains to take a long-term view of our investments and we remain confident that the steps and processes we have put in place will allow us to ride out the continued volatility and support a sustainable growth plan. As a result, our Trustees have reviewed our financial position and plans along with our risk management in light of the current environment and have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

Grant making

Kidney Care UK makes grants to hospitals and other organisations, to fund innovation and quality improvements in kidney patient care, and to help patients struggling to make ends meet. Both schemes are managed in a formal and consistent process, according to a clear and comprehensive set of guidelines. Hospital grant applications are formally peer reviewed by the Grants Committee, containing experts in their field, and scored against clearly defined and published guidelines. The Committee makes a recommendation for funding to the Board for their review and approval. In all instances where there is a conflict of interest, the Committee Member is excluded from any discussion and decision.

Our structure, governance and management

Structure

Kidney Care UK is a charitable company limited by guarantee, incorporated on 29th September 1975. The company was established under a Memorandum of Association which establishes its objects and powers and is governed under its Articles of Association. The company is registered as a company in England and Wales, registration number 1228114. Kidney Care UK is registered as a charity with the Charity Commission for England and Wales, charity number 270288 and in Scotland with the Office of the Scottish Regulator, registration number SC048198. In the event of the company being wound up members are required to contribute £10.

Trustees

The Board of Trustees is legally responsible for directing our affairs. They are Directors of the company and serve for renewable terms of three years, up to a maximum of nine years. Our articles mandate that the Board should be between 8 and 16 members and the Charity considers that 12 is the optimum number of Board members to service the Committees of the Board. As at the date of signing the Charity had a total of 13 Trustees. The Board have a wide range of skills, knowledge and experience including clinical and professional. We monitor the mix of skills and length of service to ensure that we maintain a good balance and recruit new Trustees in a timely fashion. The Trustees who served during the year are detailed on page 59.

The Board appoints all new Trustees on the advice of a Nominations Committee, and we recruit Trustees through a process of advertisement, application and interviews, and on a selection criterion that ensures a broad range of relevant skills, experience and diversity is maintained. We offer a tailored induction programme and provide further updates and training as needed. The Board makeup is reviewed annually at Board level.

The Board of Kidney Care UK are committed to good governance and recognise the importance of continued development. Following a full external governance review in 2019, the Charity conducts an annual Board self-evaluation survey, which along with any changes to the Governance Code, results in an annual Board Governance Development Plan, ensuring a culture of ongoing review and improvement. Changes to the Charity Commission Governance Code, published in December 2020, were reviewed by the Governance, Strategy & Risk Committee in 2021 and actions as a result were reflected in the annual plan to ensure continued compliance both in letter and spirit.

Decision making

The Board of Trustees meets four times a year to regularly review Kidney Care UK's general policies, strategy, budget and performance. The Board delegates the day-to-day management of the Charity to the Chief Executive and Senior Management Team. Specific responsibilities are delegated to four Board Committees, under terms of reference agreed by the Board and which report back to the Board on a regular basis. All Committees are advisory and decision-making authority is retained by the full Board.

- **Audit and Risk Committee.** This Committee is responsible for ensuring the Board fulfils its legal, ethical, and functional responsibilities through effective governance. This Committee reviews the effectiveness of the system of internal control, governance and risk management and the adequacy of external audit services liaising with the Finance and Investment Committee where required. The committee meets twice a year.
- **Finance and Investment Committee.** This Committee is responsible for ensuring the effective financial stewardship of the Charity and the management of the investment portfolio. This includes reviewing and ensuring our sustainable investment (ESG) approach is regularly considered and discussed at the Board. It makes recommendations to the Board on plans and budgets and monitors performance against these and reviews the Annual Report and Accounts. It recommends investment policy and oversees its effective implementation, ensuring compliance with regulatory requirements and Kidney Care UK's governing document. The committee meets four times a year.
- **Grants Committee.** The Grants Committee meets up to twice a year and receives and considers all applications for grants of more than £10,000 from NHS Trusts and other organisations, such as local kidney patient associations and the UK Renal Registry. It advises the Board on which grants should be approved. The Committee also regularly reviews Kidney Care UK's grant making policies. It is currently the only committee which includes lay members.
- **Staffing and Remuneration Committee.** The Committee is responsible for supporting the Board in determining the remuneration and terms and conditions of the Chief Executive, other SMT members and employees of the charity, and for overseeing the development and implementation of suitable human resources policies and procedures. The committee meets twice a year.

Key management and staff remuneration

The Senior Management Team is responsible for the day-to-day running of the Charity and comprises the Chief Executive, and the Directors of Policy, Fundraising, Marketing & Communications, Finance, and Patient Support.

The pay of the Charity's Chief Executive is reviewed annually by the Board, based on market rates and benchmarks, personal performance and scope and complexity of the role.

Volunteers

The Board and Senior Management Team are supported and advised on issues affecting patients by our Patient Advisory Group (PAG), made up of around 20 kidney patients and carers, many of whom are officers of local kidney patient associations. In addition, the Charity recruits peer supporter volunteers to deliver its peer support service, who are managed by the Peer Support and Volunteer Manager. As with Trustees, volunteers receive no remuneration, only expenses.

Our risk management

The Board of Trustees has overall responsibility for risk management at Kidney Care UK. This includes setting the risk appetite for the Charity (formal risk appetites are codified in the Charity's risk register), ensuring that there are reasonable procedures in place for the prevention and detection of major risks and ensuring that risk procedures are reviewed when issues arise. The Board formally review the Risk Policy and Register twice a year. The Board considers risks to be anything that can adversely affect our ability to achieve our objectives for people affected by kidney disease, sustain our operations, maintain our reputation or meet legal and regulatory requirements. The Charity maintains a suite of core organisational policies, covering all aspects of its work and management, which are subject to a formal, regular review cycle and supported by our committee structure.

The Board are supported by the Audit and Risk Committee (A&R) which plays a key role in overseeing management of our principal risks and provide assurance to the Board that we have adequate risk management systems and mitigating actions in place. The Committee undertakes twice yearly risk reviews and the Senior Management Team monthly meetings, chaired by the Chief Executive, oversee a comprehensive annual planning and budgeting process, performance monitoring through key performance indicators and a regular review and monitor of key strategic and operational risks. The Board consider this an effective approach to evaluate significant risks to the Charity, establish effective controls and determine necessary and prompt action.

Principal risks identified and controls

Data and information security

We have a dedicated Data and IT Manager who ensures that policies and procedures are in place to protect staff, supporter and beneficiaries' personal data, oversee regular (annual) staff training on data protection and cyber security, and ensure we comply with the highest standards stipulated in guidelines and regulations. The Charity regularly reviews its data protection and privacy policies and conducts security audits with independent third-party organisations to ensure its cyber security is robust. In 2025, as a result of the increased threat from cyber-attacks we conduct annual penetration testing to ensure that our security systems and protocols were sufficient and were pleased that only low risks were identified. In 2025 we were also pleased to retain our Cyber Essentials accreditation and we continue to ensure we maintain the Charity's high levels of security.

Service quality in patient care

Kidney Care UK's key risk is that patients receiving support from the Charity suffer harm or ineffective care as a result of our actions. The Charity has a robust safeguarding policy, including a Designated Safeguarding Officer and Deputy Safeguarding Officer, the Patient Services Team meets quarterly and receives regular high-quality training on areas such as safeguarding and Equality and Diversity, and the Charity has a published complaints policy and log, which is regularly reviewed by the SMT and the Board, along with patient and carer feedback and incident reporting. Our counselling service is staffed by fully qualified and accredited counsellors who adhere to the BACP guidelines and regulatory framework. We continue to strengthen our Safeguarding governance framework and have a named Trustee to act as the Board Safeguarding Lead.

Investment performance

Kidney Care UK's investments are managed on a total return basis. The Trustees recognise that variability in investment returns on the Charity's investment portfolio and a significant drop in the value of the portfolio to constitute the Charity's principal financial risk. A decline of 10% in the value of the portfolio triggers the discretionary investment managers and the finance advisors to enter immediate discussions with the Finance and Investment Committee. Investment managers and our advisors provide regular reports (quarterly) to the Finance and Investment Committee, which in turn reports quarterly to the Board of Trustees. The investment portfolio is diversified across two investment managers to reduce the Charity's investment risk profile, and the Board have agreed a medium risk appetite.

In 2022, the Trustees resolved to strengthen alignment with ESG investment principles through a progressive approach that does not alter the primary objective of protecting and responsible management of the Charity's current capital assets. The Finance and Investment Committee are charged with taking this programme of work forward. Our governance arrangements ensure that ESG considerations are embed into our investment discussions and oversight. Trustees receive and review reporting from our investment managers to support effective monitoring of ESG related aspects.

Investment performance

Kidney Care UK's strategic growth is dependent on achieving fundraising targets. The organisation has developed a fundraising strategy that looks to realise a diverse range of funding opportunities and to build a mature and balanced fundraising programme. We have continued to strengthen the knowledge and skills within the fundraising team to support the delivery of our strategy. The performance against income targets is carefully monitored through a monthly review of actual income against budget or reforecast by senior management and with oversight provided by the Finance and Investment Committee.

Kidney Care UK regularly reviews its fundraising procedures to ensure continued compliance with the Fundraising Code of Practice. During the year there were no identified failures in compliance with the Code, nor were any complaints received by the Charity in respect of fundraising activities. Kidney Care UK is committed to protecting vulnerable people and the wider public by ensuring that its fundraising activities are not considered to be an unreasonable intrusion on a person's privacy or an unreasonably persistent approach and do not place undue pressure on a person to give money.

Loss of key staff

In common with most small and medium sized charities, we recognise the risk of operational challenges arising from the loss of key staff. Over recent year the Charity has taken steps to reduce this risk by strengthening capacity and resilience in key roles. Having strengthened the Senior Management Team in 2022, we have continued, where resources allow, to increase capacity in areas where the pressure of work volumes and threat of "single points of failure" or lack of segregation of duties, increase our exposure. Staff engagement continues to be monitored, with the 2025 staff engagement remaining high. We regularly review our employment terms and benefits to ensure that we are a competitive employer in the Charity market.

Reference and administrative details of the charity, its trustees and advisors

Trustees

Graham Lipkin MB ChB, BSc, MD, FRCP (UK) (Chair)
Amar Radia ACA, MA (Cantab)
Angela Griffiths (Chair of Staffing and Remuneration Committee)
Caroline Price (Resigned 3 September 2025)
Grainne Walsh MSc, BSc, DipHe(Nurs), RSCN (Chair of Grants Committee)
John Henry Brown MD, FRCP, FRCPI
Lewis Temple
Madeleine Warren
Michael Zelouf
Robert Lant (Chair of Finance and Investment Committee)
Sally Hulton MD, FRCPCH, MBBCh
Sarah Hillary (Chair of Audit and Risk Committee)
Shivani Sharma CPsychol
William Richard Caldwell

Company Registered Number - 1228114 (England and Wales)
Charity Registered Number - 270288 (England and Wales) SC048198 (Scotland)

Registered office and operating office

3 The Windmills, St Mary's Close, Turk Street, Alton, Hampshire, GU34 1EF

Chief Executive

Paul Bristow

Senior Management Team

Paul Bristow
Fiona Loud
Laurie Cuthbert
Sarah Oakley
Charlotte Donnelly

Company Secretary

Shaw Gibbs Trust Corporation Limited (prev Southern Secretarial Services Ltd), Wey Court West, Union Road, Farnham, Surrey, GU9 7PT

Auditors

Kreston Reeves Audit LLP, 9 Donnington Park, 85 Birdham Road, Chichester, PO29 7AJ

Bankers

Lloyds TSB PLC, 75 Castle Street, Farnham, Surrey, GU9 7LT

Investment Managers

Cazenove Capital Management, 12 Moorgate, London EC2R 6DA
CCLA Investment Management Limited, One Angel Lane, London, EC4R 3AB

Investment Advisors

Enhance Group Limited, 3rd Floor, 29/31 Esplanade, St Helier, Jersey JE2 3QA

Statement of Trustees' responsibilities

For the year ended 31 December 2025

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' report including the Strategic report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.


The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that so far as that Trustee is aware, there is no relevant audit information of which the Charity's auditors are unaware, and that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the Charity's auditors are aware of that information.

In approving the Trustees' Annual Report, we also approve the Strategic Report included therein, in our capacity as Company Directors.

Approved and authorised for issue by the Trustees and signed on their behalf by:



Dr. G.W. Lipkin

Dr Graham Lipkin MB ChB, BSc, MD, FRCP (UK)

Chair of Trustees

Date: 29 June 2026

Auditors' report

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK

(A company limited by guarantee)

Trustees Report and Financial Statements for the year ended 31 December 2025

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK

Opinion

We have audited the financial statements of The British Kidney Patient Association t/a Kidney Care UK (the 'charity') for the year ended 31 December 2025 which comprise the Statement of financial activities, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2025 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' report including the Strategic report for the financial year for which the financial statements are prepared is consistent with the financial statements.
- the Trustees' report and the Strategic report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' report including the Strategic report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Capability of the audit in detecting irregularities, including fraud

The objectives of our audit are to identify and assess the risks of material misstatement of the financial statements due to fraud or error; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud or error; and to respond appropriately to those risks.

Based on our understanding of the Charity and sector, and through discussion with the trustees and other management (as required by auditing standards), we identified that the principal risks of non-compliance with laws and regulations related to health and safety, anti-bribery and employment law. We considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006, Statement of Recommended Practice

applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland, Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to: posting inappropriate journal entries to increase income or reduce expenditure, management bias in accounting estimates and judgemental areas of the financial statements such as accounting treatment of grants awarded not yet claimed and accounting for legacies receivable. Audit procedures performed by the engagement team included:

- Discussions with management and assessment of known or suspected instances of non-compliance with laws and regulations (including health and safety) and fraud; and
- Assessment of identified fraud risk factors; and
- Challenging assumptions and judgements made by management in its significant accounting estimates; and
- Performing analytical procedures to identify and unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and
- Confirmation of related parties with management, and review of transactions throughout the period to identify any previously undisclosed transactions with related parties outside the normal course of business; and
- Reading minutes of meetings of those charged with governance; and
- Review of significant and unusual transactions and evaluation of the underlying financial rational supporting the transactions; and
- Using data analytics to identify and test journal entries with high risk characteristics; and
- Performing substantive procedures on grant approvals at board level, progress of conditions being met and identification of grants not recognised that may indicate risks of material misstatement due to fraud; and
- Confirmation of legacy estimations, susceptible to fraud or irregularity, to solicitors' correspondence and estate accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the charitable company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- Conclude on the appropriateness of the Trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors' report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Trustees those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

Kreston Reeves Audit LLP

Lucy Hammond BSc FCA (Senior Statutory Auditor)

for and on behalf of

Kreston Reeves Audit LLP

Statutory Auditor

Chichester

Date: 6 August 2026

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	Endowment funds 2025 £	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income and endowments from:						
Donations and legacies	4	-	504,412	2,144,635	2,649,047	2,359,981
Charitable activities	5	-	1,548,474	122,070	1,670,544	941,285
Other trading activities	6	-	-	53,503	53,503	47,954
Investments	7	-	2,671	663,560	666,231	772,780
Other income	8	-	-	1,394	1,394	1,556
Total income and endowments		-	2,055,557	2,985,162	5,040,719	4,123,556
Expenditure on:						
Raising funds	9,10	-	23,401	1,062,036	1,085,437	1,048,887
Charitable activities	11	-	1,809,157	3,791,578	5,600,735	5,664,702
Total expenditure		-	1,832,558	4,853,614	6,686,172	6,713,589
Net income / (expenditure) before net (losses) / gains on investments		-	222,999	(1,868,452)	(1,645,453)	(2,590,033)
Net (losses) / gains on investments		(4,533)	-	621,916	617,383	2,144,359
Net income / (expenditure)		(4,533)	222,999	(1,246,536)	(1,028,070)	(445,674)
Transfers between funds	24	-	7,518	(7,518)	-	-
Net movement in funds		(4,533)	230,517	(1,254,054)	(1,028,070)	(445,674)
Reconciliation of funds:						
Total funds brought forward	24	95,693	297,316	26,688,763	27,081,772	27,527,446
Net movement in funds	24	(4,533)	230,517	(1,254,054)	(1,028,070)	(445,674)
Total funds carried forward	24	91,160	527,833	25,434,709	26,053,702	27,081,772

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 10 to 37 form part of these financial statements.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)
REGISTERED NUMBER: 1228114

BALANCE SHEET
AS AT 31 DECEMBER 2025

	Note	2025 £	2024 £
Fixed assets			
Intangible assets	18	78,653	72,252
Tangible assets	19	379,552	400,834
Investments	20	25,147,297	26,391,767
		<u>25,605,502</u>	<u>26,864,853</u>
Current assets			
Debtors	21	948,974	1,252,842
Cash at bank and in hand		669,618	426,447
		<u>1,618,592</u>	<u>1,679,289</u>
Current liabilities			
Creditors: amounts falling due within one year	22	(1,123,612)	(1,317,031)
Net current assets		<u>494,980</u>	<u>362,258</u>
Total assets less current liabilities		<u>26,100,482</u>	<u>27,227,111</u>
Creditors: amounts falling due after more than one year	23	(46,780)	(145,339)
Total net assets		<u><u>26,053,702</u></u>	<u><u>27,081,772</u></u>


THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)
REGISTERED NUMBER: 1228114

BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2025

	Note	2025 £	2024 £
Charity funds			
Endowment funds	24	91,160	95,693
Restricted funds	24	527,833	297,316
Unrestricted funds	24	25,434,709	26,688,763
Total funds		<u>26,053,702</u>	<u>27,081,772</u>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....
Mr Robert Lant
Chair of Finance and Investment Committee
Date: 29 June 2026

The notes on pages 10 to 37 form part of these financial statements.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	2025 £	2024 £
Cash flows from operating activities			
Net cash used in operating activities	26	(2,251,157)	(3,630,700)
Cash flows from investing activities			
Bank interest	7	406	990
Dividend income	7	665,825	771,790
Proceeds from the sale of tangible fixed assets		-	1,556
Purchase of fixed assets		(33,756)	(109,111)
Net proceeds from sale of investments		3,743,930	18,532,310
Purchase of investments		(1,952,128)	(15,471,873)
Net cash provided by investing activities		2,424,277	3,725,662
Change in cash and cash equivalents in the year		173,120	94,962
Cash and cash equivalents at the beginning of the year	27	1,178,387	1,083,425
Cash and cash equivalents at the end of the year	27	1,351,507	1,178,387

The notes on pages 10 to 37 form part of these financial statements

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1. General information

The company is a charitable company limited by guarantee, incorporated in England and Wales. The trustees on page 1 are also members of the company. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member.

The registered office is 3 The Windmills, St Mary's Close, Turk Street, Alton, GU34 1EF.

The financial statements are presented in sterling and rounded to the nearest £1.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The British Kidney Patient Association t/a Kidney Care UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis in preparing the annual financial statements. The continuing impact of the cost of living crisis has been included in the charity's forecasting and in the planning of the future and the going concern assumption takes this into consideration.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Charity has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Charity, can be reliably measured.

Grants are included in the Statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2. Accounting policies (continued)

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2.7 Intangible assets and amortisation

Intangible assets costing £1,000 or more are capitalised and recognised when future economic benefits are probable, and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over its expected useful life.

The estimated useful lives are as follows:

Computer software	- 8 years
-------------------	-----------

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2. Accounting policies (continued)

2.8 Tangible fixed assets and depreciation

Tangible fixed assets costing £1,000 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following bases:

Freehold property	- 50 years straight line
Fixtures and fittings	- 10 years straight line
Office equipment	- 3 years straight line

2.9 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2. Accounting policies (continued)

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

A contingent liability is identified and disclosed for those grants resulting from:

- a possible obligation which will only be confirmed by the occurrence of one or more uncertain future events not wholly within the trustees' control: or
- a present obligation following a grant offer where settlement is either not considered probable, or
- the amount has not been communicated in the grant offer and that amount cannot be estimated reliably.

2.13 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.14 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

2.15 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Endowment funds are funds, the income from which, are to be used in accordance with specific restrictions imposed by donors. In the prior year, the cost of raising and administering such funds are charged against the specific fund but these are now deducted from the fund values and not recognised as a separate expense. The aim and use of the endowment fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

3. Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Charity makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Legacies receivable

The Charity only recognises legacy income when it is certain to be received and can be measured or estimated with sufficient reliability. Estimations of legacy income may be based on a solicitors valuation of an estate and therefore adjustments may need to be made following actual receipts. Therefore some amounts included in the financial statements are estimations.

Critical areas of judgement:

Grants committed

The Charity recognises grants committed as a contingent liability once the grant has been approved by the Grants Committee. When the conditions of the grant are achieved by all parties, the grant is recognised as a creditor in the financial statements. A judgement is made to determine that all conditions have been satisfied.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

4. Income from donations and legacies

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £
Donations	331,102	1,917,154	2,248,256
Legacies	173,310	227,481	400,791
Total 2025	504,412	2,144,635	2,649,047

	Restricted funds 2024 £	Unrestricted funds 2024 £	Total funds 2024 £
Donations	397,570	1,176,191	1,573,761
Legacies	70,712	698,908	769,620
Grants	-	16,600	16,600
Total 2024	468,282	1,891,699	2,359,981

5. Income from charitable activities

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £
Direct patient support	1,548,474	122,070	1,670,544

	Restricted funds 2024 £	Total funds 2024 £
Direct patient support	941,285	941,285

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

6. Income from other trading activities

Income from non charitable trading activities

	Unrestricted funds 2025 £	Total funds 2025 £
Non-charitable trading - Merchandise sales	53,503	53,503

	Unrestricted funds 2024 £	Total funds 2024 £
Non-charitable trading - Merchandise sales	47,954	47,954

7. Investment income

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £
Income from listed investments	2,671	663,154	665,825
Bank interest	-	406	406
Total 2025	2,671	663,560	666,231

	Endowment funds 2024 £	Unrestricted funds 2024 £	Total funds 2024 £
Income from listed investments	2,706	769,084	771,790
Bank interest	-	990	990
Total 2024	2,706	770,074	772,780

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

8. Other incoming resources

	Unrestricted funds 2025 £	Total funds 2025 £
Other income	1,394	1,394

	Unrestricted funds 2024 £	Total funds 2024 £
Other income	1,556	1,556

9. Investment management costs

	Unrestricted funds 2025 £	Total funds 2025 £
Investment management fees	73,266	73,266

	Endowment funds 2024 £	Unrestricted funds 2024 £	Total funds 2024 £
Investment management fees	72	121,431	121,503

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

10. Expenditure on raising funds

Costs of raising voluntary income

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £
Costs of raising voluntary income	23,401	988,770	1,012,171

	Restricted funds 2024 £	Unrestricted funds 2024 £	Total funds 2024 £
Costs of raising voluntary income	3,113	924,271	927,384

11. Analysis of expenditure on charitable activities

Summary by fund type

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total 2025 £
Direct patient support	1,809,157	3,791,578	5,600,735

	Endowment funds 2024 £	Restricted funds 2024 £	Unrestricted funds 2024 £	Total 2024 £
Direct patient support	2,634	1,391,243	4,270,825	5,664,702

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

12. Analysis of expenditure by activities

	Activities undertaken directly 2025 £	Grant funding of activities 2025 £	Support costs 2025 £	Total funds 2025 £
Direct patient support	3,406,926	860,096	1,333,713	5,600,735

	Activities undertaken directly 2024 £	Grant funding of activities 2024 £	Support costs 2024 £	Total funds 2024 £
Direct patient support	2,889,345	1,460,416	1,314,941	5,664,702

Analysis of direct costs

	Direct patient support 2025 £	Total funds 2025 £
Counselling	172,238	172,238
Advocacy	1,862,784	1,862,784
Influencing policy	226,406	226,406
Patient information	749,119	749,119
Other direct support	396,379	396,379
Total 2025	3,406,926	3,406,926

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

12. Analysis of expenditure by activities (continued)

Analysis of direct costs (continued)

	Direct patient support 2024 £	Total funds 2024 £
Counselling	157,530	157,530
Advocacy	1,376,287	1,376,287
Influencing policy	228,250	228,250
Patient information	775,984	775,984
Other direct support	351,294	351,294
Total 2024	2,889,345	2,889,345

Staff costs comprising wages and salaries, social security costs and pension costs are allocated across the different services provided.

Analysis of support costs

	Direct patient support 2025 £	Total funds 2025 £
Governance	214,724	214,724
Finance	163,074	163,074
Information technology	241,431	241,431
Human resources	153,590	153,590
Premises and facilities	181,861	181,861
Communications	280,133	280,133
Grant staff and administration costs	98,900	98,900
Total 2025	1,333,713	1,333,713

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

12. Analysis of expenditure by activities (continued)

Analysis of support costs (continued)

	Direct patient support 2024 £	Total funds 2024 £
Governance	193,223	193,223
Finance	157,757	157,757
Information technology	205,426	205,426
Human resources	170,436	170,436
Premises and facilities	180,738	180,738
Communications	277,463	277,463
Grant staff and administration costs	129,898	129,898
Total 2024	<u>1,314,941</u>	<u>1,314,941</u>

Staff costs comprising wages and salaries, social security costs and pension costs are allocated across the different services provided.

13. Analysis of grant funding activities

	Grants to Institutions 2025 £	Grants to Individuals 2025 £	Total funds 2025 £
Grants - patient support	<u>166,211</u>	<u>693,885</u>	<u>860,096</u>

	Grants to Institutions 2024 £	Grants to Individuals 2024 £	Total funds 2024 £
Grants - patient support	<u>542,795</u>	<u>917,621</u>	<u>1,460,416</u>

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

Grants by type

	2025 £	2024 £
Post funding, projects and equipment	42,226	385,553
Dialysis freedom	52,169	48,496
Small grants	1,880	9,232
Grants to patients	693,885	917,621
Research/Development	69,936	58,025
Mount Cook	-	41,489
Total grants	860,096	1,460,416

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

	2025 £	2024 £
Grants by Institution		
Alder Hey Children's Hospital	2,500	4,000
Belfast City Hospital	4,000	1,140
Bristol Royal Hospital for Children	5,534	7,212
Dialysis Freedom	52,169	48,496
Evelina Children's Hospital	-	3,000
Great Ormond Street Hospital for Children	2,500	3,000
Guy's Hospital	-	1,256
Leeds Children's Hospital	2,500	5,500
Leeds General Infirmary	1,000	2,000
Leicester General Hospital	2,000	-
Manchester Children's Hospital	2,500	4,000
Manchester Royal Infirmary	-	2,000
Mount Cook	-	41,489
Newcastle, Freeman Hospital	-	2,000
Nottingham Children's Hospital	10,500	11,710
Nottingham University Hospital NHS Trust	2,000	2,000
Other grants, including small grants	96,533	70,214
Queen Alexandra Hospital - Wessex Kidney Centre	-	1,500
Queen Elizabeth Birmingham	-	1,350
Renal Psychological Therapists	-	4,000
Renal Social Workers	10,000	9,000
Royal Belfast Hospital for Sick Children	-	5,000
Shrewsbury and Telford Hospital NHS Trust	-	10,754
Southampton Children's Hospital	-	5,000
South East Scotland Kidney Patient Association	-	48,000
The British Dietetic Association	4,000	-
The Renal Association	-	310,677
University Hospital Southampton	3,000	-
Lapsed or cancelled grants for prior years	(34,525)	(61,503)
Total grants to institutions	166,211	542,795

Activities undertaken through the Mount Cook initiative continue; however, they are no longer classified as grant expenditure. As the initiative has evolved, the Charity has brought this programme in house. For the year ended 31 December 2025, expenditure of £32,348 relating to the Mount Cook initiative is recognised as direct charitable activity expenditure.

14. Taxation

The Association is a charity and is entitled to exemption from taxation on its charitable income and profits by virtue of Section 505 of the Income and Corporation Taxes Act 1988.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

15. Auditors' remuneration

The auditors' remuneration amounts to an auditor fee of £19,850 (2024 - £18,650), and the amounts in relation to statutory accounts preparation payable to a fellow group entity of the auditors of £3,950 (2024 - £2,650).

16. Staff costs

	2025 £	2024 £
Wages and salaries	3,323,298	2,813,306
Social security costs	379,931	260,109
Pension costs	270,811	221,695
	<u>3,974,040</u>	<u>3,295,110</u>

The average number of persons employed by the Charity during the year was as follows:

	2025 No.	2024 No.
Grants and patient aid (including support costs)	14	10
Fundraising	15	13
Advocacy service	53	38
Counselling service	6	6
Policy service	3	3
Management and administration	21	21
	<u>112</u>	<u>91</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2025 No.	2024 No.
£60k - £70k	-	1
£70k - £80k	2	1
£80k - £90k	1	1
£100k - £110k	1	1

The key management personnel of the charity comprise the trustees, the Chief Executive Officer, Policy Director, Director of Marketing and Communications, Finance Director and Director of Patient Support Services. The total employee benefits of the key management personnel of the charity were £476,317 (2024: £426,412), including employer pension contributions £35,413 (2024: £34,286).

17. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL).

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

17. Trustees' remuneration and expenses (continued)

During the year ended 31 December 2025, travel expenses totalling £2,732 were reimbursed or paid directly to 4 Trustees (2024 - £1,024 to 3 Trustees).

There is a total of £2,778 (2024: £2,788) paid by the charity in relation to trustee indemnity insurance on behalf of trustees.

18. Intangible assets

	Computer software £
Cost	
At 1 January 2025	72,273
Additions	16,927
At 31 December 2025	<u>89,200</u>
Amortisation	
At 1 January 2025	21
Charge for the year	10,526
At 31 December 2025	<u>10,547</u>
Net book value	
At 31 December 2025	<u><u>78,653</u></u>
At 31 December 2024	<u><u>72,252</u></u>

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

19. Tangible fixed assets

	Freehold property £	Fixtures and fittings £	Office equipment £	Total £
Cost or valuation				
At 1 January 2025	395,595	105,296	145,396	646,287
Additions	-	-	16,829	16,829
Disposals	-	-	(10,685)	(10,685)
At 31 December 2025	<u>395,595</u>	<u>105,296</u>	<u>151,540</u>	<u>652,431</u>
Depreciation				
At 1 January 2025	79,067	67,583	98,803	245,453
Charge for the year	4,331	7,682	26,098	38,111
On disposals	-	-	(10,685)	(10,685)
At 31 December 2025	<u>83,398</u>	<u>75,265</u>	<u>114,216</u>	<u>272,879</u>
Net book value				
At 31 December 2025	<u>312,197</u>	<u>30,031</u>	<u>37,324</u>	<u>379,552</u>
At 31 December 2024	<u>316,528</u>	<u>37,713</u>	<u>46,593</u>	<u>400,834</u>

The Charity's premises were acquired in 2011. The land value was £100,000.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

20. Fixed asset investments

	Listed investments £
Cost or valuation	
At 1 January 2025	26,391,767
Additions	1,952,128
Disposals	(2,944,941)
Revaluations	(251,657)
	<u>25,147,297</u>
At 31 December 2025	
	<u>25,147,297</u>
Net book value	
At 31 December 2025	25,147,297
At 31 December 2024	<u>26,391,767</u>

Investments at market value comprise:

	UK 2025 £	Overseas 2025 £	Total funds 2025 £
Listed investments	14,846,683	9,618,725	24,465,408
Cash held by investment managers	681,889	-	681,889
	<u>15,528,572</u>	<u>9,618,725</u>	<u>25,147,297</u>
Total 2025			

The historical cost of the investments total £21,812,992 (2024: £23,290,244).

	UK 2024 £	Overseas 2024 £	Total funds 2024 £
Listed investments	15,866,601	9,773,226	25,639,827
Cash held by investment managers	751,940	-	751,940
	<u>16,618,541</u>	<u>9,773,226</u>	<u>26,391,767</u>

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

	2025 £	2024 £
Fixed interest	3,190,488	2,932,249
Equities	19,050,452	19,819,603
Property	518,724	502,470
Alternatives	1,705,744	2,385,505
Cash held by investment managers	681,889	751,940
	<u>25,147,297</u>	<u>26,391,767</u>

21. Debtors

	2025 £	2024 £
Due within one year		
Trade debtors	45,541	268,310
Other debtors	512,461	656,677
Prepayments and accrued income	390,972	327,855
	<u>948,974</u>	<u>1,252,842</u>

22. Creditors: Amounts falling due within one year

	2025 £	2024 £
Trade creditors	218,361	241,057
Accruals and deferred income	607,120	636,962
Other taxation and social security	73,928	57,047
Other creditors	120,220	102,348
Grants payable	103,983	279,617
	<u>1,123,612</u>	<u>1,317,031</u>

23. Creditors: Amounts falling due after more than one year

	2025 £	2024 £
Grants payable	<u>46,780</u>	<u>145,339</u>

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

24. Statement of funds

Statement of funds - current year

	Balance at 1 January 2025 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2025 £
Unrestricted funds						
Designated funds						
Designated Fund	26,200,000	-	-	(1,200,000)	-	25,000,000
General funds						
General Fund	488,763	2,985,162	(4,853,614)	1,192,482	621,916	434,709
Total Unrestricted funds	26,688,763	2,985,162	(4,853,614)	(7,518)	621,916	25,434,709
Endowment funds						
Endowment Fund	95,693	-	-	-	(4,533)	91,160

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

24. Statement of funds (continued)

	Balance at 1 January 2025 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2025 £
Restricted funds						
Kidney Machine	34,882	-	-	-	-	34,882
Children and Young activity breaks	16,018	2,671	(18,689)	-	-	-
My Renal Care	15,000	-	-	-	-	15,000
Patient Information	64,582	168,749	(78,537)	(1,909)	-	152,885
Exeter and District KPA	10,216	-	(822)	-	-	9,394
British Gas Energy Trust	70,399	192,634	(207,075)	(13,471)	-	42,487
Northern Ireland	-	-	(13,800)	23,679	-	9,879
The Advocacy Officer Fund	14,347	40,000	(35,973)	-	-	18,374
Wales and West - VCMA1	-	268,094	(267,313)	(781)	-	-
Wales and West - VCMA2	-	1,156,961	(1,156,961)	-	-	-
Other	71,872	39,937	(25,376)	-	-	86,433
Scotland fund	-	158,709	(210)	-	-	158,499
Tejas Young Adult Holiday Fund	-	700	(700)	-	-	-
Kidney Kitchen Fund	-	5,000	(5,000)	-	-	-
Peer support	-	20,000	(20,000)	-	-	-
Respite Fund	-	2,102	(2,102)	-	-	-
	<u>297,316</u>	<u>2,055,557</u>	<u>(1,832,558)</u>	<u>7,518</u>	<u>-</u>	<u>527,833</u>
Total of funds	<u>27,081,772</u>	<u>5,040,719</u>	<u>(6,686,172)</u>	<u>-</u>	<u>617,383</u>	<u>26,053,702</u>

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

24. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 January 2024 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2024 £
Unrestricted funds						
Designated funds						
Designated Funds	26,700,000	-	-	(500,000)	-	26,200,000
General funds						
General Fund	431,956	2,711,283	(5,316,527)	523,198	2,138,853	488,763
Total Unrestricted funds	27,131,956	2,711,283	(5,316,527)	23,198	2,138,853	26,688,763
Endowment funds						
Endowment Fund	90,187	2,706	(2,706)	-	5,506	95,693

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

24. Statement of funds (continued)

	Balance at 1 January 2024 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2024 £
Restricted funds						
Kidney Machine	34,882	-	-	-	-	34,882
Children and Young activity breaks	15,903	41,311	(41,196)	-	-	16,018
My Renal Care	15,000	-	-	-	-	15,000
Patient Information	182,131	105,000	(221,876)	(673)	-	64,582
Exeter and District KPA	13,198	-	(2,982)	-	-	10,216
British Gas Energy Trust	41,414	184,917	(155,932)	-	-	70,399
Northern Ireland	-	5,792	(5,792)	-	-	-
Shared care	-	1,600	(1,600)	-	-	-
The Advocacy Officer Fund	-	50,000	(35,653)	-	-	14,347
Hardship, welfare, benefits	-	1,000	(1,000)	-	-	-
Wales and West - VCMA1	-	250,250	(250,250)	-	-	-
Wales and West - VCMA2	-	691,035	(668,510)	(22,525)	-	-
Other	2,775	78,662	(9,565)	-	-	71,872
	<u>305,303</u>	<u>1,409,567</u>	<u>(1,394,356)</u>	<u>(23,198)</u>	<u>-</u>	<u>297,316</u>
 Total of funds	 <u>27,527,446</u>	 <u>4,123,556</u>	 <u>(6,713,589)</u>	 <u>-</u>	 <u>2,144,359</u>	 <u>27,081,772</u>

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

24. Statement of funds (continued)

Designated funds represent amounts held as tangible fixed assets and sums that the Trustees have set aside to be used for the payment of future regularly occurring grants and running costs. These sums are not fully committed at the balance sheet date and are held as investments to generate income to facilitate future grant payments. The transfer in the year was made to offset the impact of the in year deficit.

The Endowment Fund is an endowment received from Chris Perrot Critical Illness Trust. The income from the Endowment Fund is also used to provide holidays for children with kidney problems.

The Kidney Machine Fund is from a specific legacy bequeathed for the provision of dialysis machines.

The Children and Young Activity Breaks Fund relates to specific donations received by the Charity to help fund activity breaks for children and young adults.

My Renal Care Fund relates to communication support for a larger bid to NHSX by Wessex Kidney Centre to promote and develop the MyRenalCare app.

The Patient Information Fund relates to specific donations received to help us develop and improve our patient information services, be this in the form of webinars, blogs, articles in our magazine Kidney Matters or a brochure. The transfer in the year relates to monies spent on small equipment.

The Exeter and District KPA Fund exists to financially support kidney patients under the care of the Exeter and Devon based hospitals.

The British Gas and Energy Trust (BGET) fund relates to funding provided by BGET to set-up and support our Money and Energy Advice service. The money and energy advisors work on a one-to-one basis with people with kidney disease, assessing their needs and identifying sources of support to resolve practical, financial, and psychosocial challenges. The transfer in the year relates to other costs agreed by BGET as chargeable to this fund.

The Northern Ireland Fund relates to donations received to support kidney patients in Northern Ireland and the Scotland Fund relates to donations received to support kidney patients in Scotland.

The Shared Care fund relates to specific donation received to support our Shared Care project.

The Advocacy Officer Fund relates to specific donations received to fund the Charity's Patient Support and Advocacy Service.

The Hardship, Welfare and Benefits Fund relates to specific donations received to support individuals in need.

The Wales and West Project relates to the expansion of our Advocacy service within Wales. The project is focused on providing access free, impartial guidance and support that centres around welfare with a focus on working together to help maximise income, reduce utility-related expenditure and support overall wellbeing. The transfer in the year relates to monies spent on IT equipment.

The Kidney Kitchen Fund relates to income received specifically to fund the work and development of patient information related to the Kidney Kitchen.

The Tejas Young Adult Holiday Fund relates to income given to be spent on funding holidays for young adults.

The Peer Support Fund relates to funding provided to support the provision of our Peer Support service.

The Respite Fund relates to income generated to support those beneficiaries in need of a respite break.

The Other fund relates to small donations received to support certain areas of our charitable activities, we

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

24. Statement of funds (continued)

record such donations and related expenditure through this fund.

25. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Endowment funds 2025 £	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £
Tangible fixed assets	-	-	379,552	379,552
Intangible fixed assets	-	-	78,653	78,653
Fixed asset investments	91,160	-	25,056,137	25,147,297
Current assets	-	527,833	1,090,759	1,618,592
Creditors due within one year	-	-	(1,123,612)	(1,123,612)
Creditors due in more than one year	-	-	(46,780)	(46,780)
Total	91,160	527,833	25,434,709	26,053,702

Analysis of net assets between funds - prior year

	Endowment funds 2024 £	Restricted funds 2024 £	Unrestricted funds 2024 £	Total funds 2024 £
Tangible fixed assets	-	-	400,834	400,834
Intangible fixed assets	-	-	72,252	72,252
Fixed asset investments	95,693	-	26,296,074	26,391,767
Current assets	-	297,316	1,381,973	1,679,289
Creditors due within one year	-	-	(1,317,031)	(1,317,031)
Creditors due in more than one year	-	-	(145,339)	(145,339)
Total	95,693	297,316	26,688,763	27,081,772

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

26. Reconciliation of net movement in funds to net cash flow from operating activities

	2025 £	2024 £
Net expenditure for the year (as per Statement of Financial Activities)	(1,028,070)	(445,674)
Adjustments for:		
Depreciation and amortisation charges	48,637	39,733
(Gains)/losses on investments	(617,383)	(2,144,359)
Dividends, interests and rents from investments	(666,231)	(772,780)
Loss/(profit) on the sale of fixed assets	-	(566)
Decrease/(increase) in debtors	303,868	(688,997)
Increase/(decrease) in creditors	(291,978)	381,943
Net cash used in operating activities	(2,251,157)	(3,630,700)

27. Analysis of cash and cash equivalents

	2025 £	2024 £
Cash in hand	669,618	426,447
Cash held as part of investments	681,889	751,940
Total cash and cash equivalents	1,351,507	1,178,387

28. Analysis of changes in net debt

	At 1 January 2025 £	Cash flows £	At 31 December 2025 £
Cash at bank and in hand	426,447	243,171	669,618
	426,447	243,171	669,618

29. Pension commitments

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £270,811 (2024: £221,695) and the amount owing at the year end was £32,255 (2024: £32,498).

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

30. Operating lease commitments

At 31 December 2025 the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	2025 £	2024 £
Other		
Not later than 1 year	2,194	2,194
Later than 1 year and not later than 5 years	4,933	7,127
	<u>7,127</u>	<u>9,321</u>
	2025 £	2024 £
Land and Buildings		
Not later than 1 year	23,067	23,067
Later than 1 year and not later than 5 years	14,047	14,047
	<u>37,114</u>	<u>37,114</u>

Operating lease rentals recognised as an expense in the Statement of financial activities were £25,700 (2024: £28,425).

31. Related party transactions

In the year, donations received without conditions from trustees totalled £185 (2024: £6,672). There were no other related party transactions in either year.

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

32. Prior year statement of financial activities

	Endowment funds 2024 £	Restricted funds 2024 £	Unrestricted funds 2024 £	Total funds 2024 £
Income and endowments from:				
Donations and legacies	-	468,282	1,891,699	2,359,981
Charitable activities	-	941,285	-	941,285
Other trading activities	-	-	47,954	47,954
Investments	2,706	-	770,074	772,780
Other income	-	-	1,556	1,556
Total income and endowments	2,706	1,409,567	2,711,283	4,123,556
Expenditure on:				
Raising funds	72	3,113	1,045,702	1,048,887
Charitable activities	2,634	1,391,243	4,270,825	5,664,702
Total expenditure	2,706	1,394,356	5,316,527	6,713,589
Net income / (expenditure) before net (losses) / gains on investments	-	15,211	(2,605,244)	(2,590,033)
Net (losses) / gains on investments	5,506	-	2,138,853	2,144,359
Net income / (expenditure)	5,506	15,211	(466,391)	(445,674)
Transfer between funds	-	(23,198)	23,198	-
Net movement in funds	5,506	(7,987)	(443,193)	(445,674)
Reconciliation of funds:				
Total funds brought forward	90,187	305,303	27,131,956	27,527,446
Net movement in funds	5,506	(7,987)	(443,193)	(445,674)
Total funds carried forward	95,693	297,316	26,688,763	27,081



Kidney Care UK is the UK's leading kidney patient support charity, providing practical, financial and emotional assistance for kidney patients and their families throughout the UK. We believe that no one should face kidney disease alone.

For further details of all the support we provide to people living with kidney disease, please visit our website

www.kidneycareuk.org or call us on 0808 801 00 00

www.kidneycareuk.org | info@kidneycareuk.org

01420 541 424 | Lines open 9am - 5pm, Monday–Friday

Kidney Care UK, 3 The Windmills, St Mary's Close, Alton, GU34 1EF

©Kidney Care UK. Kidney Care UK is the operating name of the British Kidney Patient Association. A charitable company limited by guarantee. Registered in England and Wales (1228114). A charity registered in England and Wales (270288), and Scotland (SC048198).

